| Year |
Title |
Altmetric |
| 2020
|
RE Letter to the Editor: Prehypertension is associated with multiple poor maternal and fetal outcomes, by Giovanni Sisti
2020
|
|
| 2020
|
How to deal with the occurrence of rare drug-induced adverse events: the example of sprue-like enteropathy induced by olmesartan medoxomil and other angiotensin-receptor blockers
2020
|
|
| 2020
|
Intensive vs Standard Blood Pressure Control in Adults 80 Years or Older: A Secondary Analysis of the Systolic Blood Pressure Intervention Trial
2020
|
|
| 2020
|
Aortic blood pressure and arterial stiffness in patients with controlled resistant and non-resistant hypertension
2020
|
|
| 2020
|
The AJMS Celebrates # 200!
2020
|
|
| 2020
|
The role of exercise in the reversal of IGF-1 deficiencies in microvascular rarefaction and hypertension
2020
|
|
| 2020
|
The Health Outcomes Prevention and Evaluation 4 (HOPE 4) project: A successful community-based intervention to lower cardiovascular risk in people with hypertension
2020
|
|
| 2020
|
Antihypertensive Medication Adherence and Confirmation of True Refractory Hypertension
2020
|
|
| 2020
|
Chronic Hypertension in Pregnancy
2020
|
|
| 2020
|
Orthostatic Hypotension, Cardiovascular Outcomes, and Adverse Events: Results from SPRINT
2020
|
|
| 2020
|
Race-based and sex-based differences in bioactive lipid mediators after myocardial infarction
2020
|
|
| 2020
|
Report of the National Heart, Lung, and blood institute working group on hypertension barriers to translation
2020
|
|
| 2019
|
Heart Failure Prevention in Older Patients Using Intensive Blood Pressure Reduction: Potential Role of Diuretics
2019
|
|
| 2019
|
State of the Art: the Not-So-Great Wall of America
2019
|
|
| 2019
|
What is the first choice for blood pressure treatment?
2019
|
|
| 2019
|
Systolic blood pressure control prevents cognitive decline and slows development of white matter lesions in the brain: the SPRINT MIND study outcomes
2019
|
|
| 2019
|
Clinical characteristics, antihypertensive medication use and blood pressure control among patients with treatment-resistant hypertension: The Survey of PatIents with treatment ResIstant hyperTension study
2019
|
|
| 2019
|
Sex Differences in Hypertension and Stroke Risk in the REGARDS Study: A Longitudinal Cohort Study
2019
|
|
| 2019
|
The PARAGON-Heart failure trial–another disappointment for heart failure patients with hypertension and preserved ejection fraction
2019
|
|
| 2019
|
Masked uncontrolled hypertension is not attributable to medication nonadherence
2019
|
|
| 2019
|
Association of intensive vs standard blood pressure control with cerebral white matter lesions
2019
|
|
| 2019
|
Effect of Intensive Blood Pressure Reduction on Left Ventricular Mass, Structure, Function, and Fibrosis in the SPRINT-HEART
2019
|
|
| 2019
|
The PARAGON Heart Failure trial–ongoing investigation of the angiotensin receptor antagonist/neprilysin inhibitor sacubitril/valsartan in heart failure patients with hypertension and preserved ejection fraction
2019
|
|
| 2019
|
Six-Month Results of Treatment-Blinded Medication Titration for Hypertension Control After Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in the RADIANCE-HTN SOLO Trial
2019
|
|
| 2019
|
Need for multiple risk reduction strategies in clinical trials enrolling high risk patients - FOURIER investigating PCSK-9 inhibitor to lower cholesterol revisited
2019
|
|
| 2019
|
Epicardial Adipose Tissue and Cardiovascular Disease
2019
|
|
| 2019
|
Prevention of Heart Failure in Hypertension—Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study
2019
|
|
| 2019
|
Plasma xanthine oxidase activity is related to increased sodium and left ventricular hypertrophy in resistant hypertension
2019
|
|
| 2019
|
Sustained blood pressure control and coronary heart disease, stroke, heart failure, and mortality: An observational analysis of ALLHAT
2019
|
|
| 2019
|
Urinary biomarkers of tubular damage are associated with mortality but not cardiovascular risk among systolic blood pressure intervention trial participants with chronic kidney disease
2019
|
|
| 2019
|
Treatment of Resistant and Refractory Hypertension
2019
|
|
| 2019
|
Will we ever use angiotensin receptor neprilysin inhibition (ARNi) for the treatment of hypertension?
2019
|
|
| 2019
|
Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial
2019
|
|
| 2019
|
New data on antihypertensive drugs and risk of cancer: should we worry?
2019
|
|
| 2019
|
Blood Pressure and the Electronic Health Record: A Work in Progress
2019
|
|
| 2019
|
Induced pluripotent stem cell-derived endothelial cells attenuate lipopolysaccharide-induced acute lung injury
2019
|
|
| 2019
|
Lower blood pressure thresholds raise the bar in pregnancy
2019
|
|
| 2019
|
Out-of-Clinic Sympathetic Activity Is Increased in Patients with Masked Uncontrolled Hypertension
2019
|
|
| 2018
|
PTH, FGF23, and intensive blood pressure lowering in chronic kidney disease participants in SPRINT
2018
|
|
| 2018
|
Obesity and Pulmonary Hypertension
2018
|
|
| 2018
|
2018 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension
2018
|
|
| 2018
|
Effect of sleeve gastrectomy on hypertension
2018
|
|
| 2018
|
Association of Clinical and Social Factors with Excess Hypertension Risk in Black Compared with White US Adults
2018
|
|
| 2018
|
Novel Medical Treatments for Hypertension and Related Comorbidities
2018
|
|
| 2018
|
Number of measurements needed to obtain a reliable estimate of home blood pressure: Results from the improving the detection of hypertension study
2018
|
|
| 2018
|
Prognostic value of myocardial perfusion imaging performed pre-renal transplantation: post-transplantation follow-up and outcomes
2018
|
|
| 2018
|
Revisiting ASCOT 16 years later
2018
|
|
| 2018
|
Intensive blood pressure lowering prevents mild cognitive impairment and possible dementia and slows development of white matter lesions in brain: the SPRINT Memory and Cognition IN Decreased Hypertension (SPRINT MIND) study
2018
|
|
| 2018
|
Effects of intensive systolic blood pressure lowering on cardiovascular events and mortality in patients with type 2 diabetes mellitus on standard glycemic control and in those without diabetes mellitus: Reconciling results from ACCORD BP and SPRINT
2018
|
|
| 2018
|
Pulse wave velocity and central aortic pressure in systolic blood pressure intervention trial participants
2018
|
|
| 2018
|
Take a blood pressure pill or benefit from renal denervation?
2018
|
|
| 2018
|
Visceral Adipose Tissue Accumulation and Residual Cardiovascular Risk
2018
|
|
| 2018
|
Final Farewell to Alberto Zanchetti MD.
2018
|
|
| 2018
|
Renal denervation achieved by endovascular delivery of ultrasound in RADIANCE-HTN SOLO or by radiofrequency energy in SPYRAL HTN-OFF and SPYRAL-ON lowers blood pressure
2018
|
|
| 2018
|
Case of refractory hypertension controlled after aortic and mitral valve replacement and coronary artery bypass grafting
2018
|
|
| 2018
|
In memoriam: Alberto Zanchetti.
2018
|
|
| 2018
|
O-linked β-N-acetylglucosamine modification of A20 enhances the inhibition of NF-κB (nuclear factor-κB) activation and elicits vascular protection after acute endoluminal arterial injury
2018
|
|
| 2018
|
Reply
2018
|
|
| 2018
|
Blood pressure measurement in SPRINT (Systolic Blood Pressure Intervention Trial)
2018
|
|
| 2018
|
Gender, blood pressure, and cardiovascular and renal outcomes in adults with hypertension fromthe Systolic Blood Pressure InterventionTrial
2018
|
|
| 2018
|
Long-term efficacy and tolerability of azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide in chronic kidney disease
2018
|
|
| 2018
|
Hypertension
2018
|
|
| 2018
|
New 2017 American Heart Association and American College of Cardiology guideline for hypertension in the adults: major paradigm shifts, but will they help to fight against the hypertension disease burden?
2018
|
|
| 2018
|
Accuracy of blood pressure measurement devices in pregnancy: A systematic review of validation studies
2018
|
|
| 2018
|
VEGF nanoparticles repair the heart after myocardial infarction
2018
|
|
| 2018
|
Challenges in oscillometric blood pressure measurement in atrial fibrillation: looking for practical solutions
2018
|
|
| 2018
|
Impact of intensive versus standard blood pressure management by tertiles of blood pressure in SPRINT (Systolic Blood Pressure Intervention Trial)
2018
|
|
| 2018
|
Refractory hypertension is not attributable to intravascular fluid retention as determined by intracardiac volumes
2018
|
|
| 2018
|
Sprinting toward the optimal blood pressure target for hypertensive patients
2018
|
|
| 2018
|
What is the most appropriate target SBP in persons with hypertension and diabetes mellitus?
2018
|
|
| 2017
|
The Matrikine Acetylated Proline-Glycine-Proline Couples Vascular Inflammation and Acute Cardiac Rejection
2017
|
|
| 2017
|
Renal denervation in hypertension: is it the end or the beginning of a SPYRAL?
2017
|
|
| 2017
|
Baseline quality of life and risk of stroke in the ALLHAT study (antihypertensive and lipid-lowering treatment to prevent heart attack trial)
2017
|
|
| 2017
|
Risk stratification of sudden cardiac death in hypertension
2017
|
|
| 2017
|
Masked Hypertension
2017
|
|
| 2017
|
Treatment strategies for comorbid conditions lower residual risk in patients with treated hypertension: FOURIER and other randomized outcome trials
2017
|
|
| 2017
|
Cognitive Function and Kidney Disease: Baseline Data From the Systolic Blood Pressure Intervention Trial (SPRINT)
2017
|
|
| 2017
|
Effects of intensive BP control in CKD
2017
|
|
| 2017
|
Regression of Left Ventricular Mass After Bariatric Surgery
2017
|
|
| 2017
|
White-Coat Effect Is Uncommon in Patients with Refractory Hypertension
2017
|
|
| 2017
|
Cost-effectiveness of intensive versus standard blood-pressure control
2017
|
|
| 2017
|
Effect of intensive blood-pressure treatment on patient-reported outcomes
2017
|
|
| 2017
|
Incident cardiovascular disease among adults with blood pressure <140/90 mm Hg
2017
|
|
| 2017
|
Hypertension in Women: Recent Advances and Lingering Questions
2017
|
|
| 2017
|
Race and sex differences in ambulatory blood pressure measures among HIV+ adults
2017
|
|
| 2017
|
The INTERSTROKE Study: hypertension is by far the most important modifiable risk factor for stroke
2017
|
|
| 2017
|
Distinctive Risk Factors and Phenotype of Younger Patients with Resistant Hypertension: Age is Relevant
2017
|
|
| 2017
|
Obesity-Associated Hypertension: the Upcoming Phenotype in African-American Women
2017
|
|
| 2017
|
123I-mIBG scintigraphy: Clinical tool for assessing renal sympathetic activity?
2017
|
|
| 2017
|
Effect of Intensive Blood Pressure Treatment on Heart Failure Events in the Systolic Blood Pressure Reduction Intervention Trial
2017
|
|
| 2017
|
Hypertension and Its Complications in a Young Man with Autoimmune Disease
2017
|
|
| 2017
|
Induced pluripotent stem cell-derived endothelial cells overexpressing interleukin-8 receptors a/b and/or c-c chemokine receptors 2/5 inhibit vascular injury response
2017
|
|
| 2017
|
The INTERSALT Study and the complex relationship between salt intake and blood pressure
2017
|
|
| 2017
|
The technical report on sodiumintake and cardiovascular disease in low- and middleincome countries by the joint working group of theWorld Heart Federation, the European Society of Hypertension and the European Public Health Association
2017
|
|
| 2017
|
Assessment of vascular function in low socioeconomic status preschool children: a pilot study
2017
|
|
| 2017
|
On-Treatment Blood Pressure and Cardiovascular Outcomes in Older Adults with Isolated Systolic Hypertension
2017
|
|
| 2017
|
Pathophysiology and Potential Non-Pharmacologic Treatments of Obesity or Kidney Disease Associated Refractory Hypertension
2017
|
|
| 2017
|
The Global Burden of Disease Study 2015 and Blood Pressure
2017
|
|
| 2017
|
11-beta dehydrogenase type 2 activity is not reduced in treatment resistant hypertension
2017
|
|
| 2017
|
Association between chronic kidney disease and cancer mortality: A report from the ALLHAT
2017
|
|
| 2017
|
Association of 3 different antihypertensive medications with hip and pelvic fracture risk in older adults secondary analysis of a randomized clinical trial
2017
|
|
| 2016
|
Electrocardiographic measures of left ventricular hypertrophy in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
2016
|
|
| 2016
|
Smad3-mSin3A-HDAC1 Complex is Required for TGF-β1-Induced Transcriptional Inhibition of PPARγ in Mouse Cardiac Fibroblasts
2016
|
|
| 2016
|
Blood Pressure in 2016: increased impact factor and change of editors
2016
|
|
| 2016
|
Orthostatic changes in systolic blood pressure among SPRINT participants at baseline
2016
|
|
| 2016
|
Should Patients with Cardiovascular Risk Factors Receive Intensive Treatment of Hypertension to <120/80 mm Hg Target?: A Protagonist View from the SPRINT Trial (Systolic Blood Pressure Intervention Trial)
2016
|
|
| 2016
|
BP Targets in Hypertension: What Should We Do Now That SPRINT Is Out?
2016
|
|
| 2016
|
Body Mass Index Predicts 24-Hour Urinary Aldosterone Levels in Patients with Resistant Hypertension
2016
|
|
| 2016
|
The polypill: an emerging treatment alternative for secondary prevention of cardiovascular disease
2016
|
|
| 2016
|
OS 24-04 A PILOT STUDY ASSESSING THE FEASIBILITY OF VASCULAR FUNCTION IN LOW SOCIOECONOMIC STATUS PRESCHOOL CHILDREN.
2016
|
|
| 2016
|
OS 33-02 IN PATIENTS WITH RESISTANT HYPERTENSION INCREASED 24-H URINARY CORTISOL LEVEL PREDICT INCREASED BODY MASS INDEX.
2016
|
|
| 2016
|
OS 33-02 IN PATIENTS WITH RESISTANT HYPERTENSION INCREASED 24-H URINARY CORTISOL LEVEL PREDICT INCREASED BODY MASS INDEX.
2016
|
|
| 2016
|
SY 11-3 HYPERTENSION IN WOMEN: MORE DANGEROUS THAN IN MEN?
2016
|
|
| 2016
|
SY 11-3 HYPERTENSION IN WOMEN: MORE DANGEROUS THAN IN MEN?
2016
|
|
| 2016
|
The effects of urate lowering therapy on inflammation, endothelial function, and blood pressure (SURPHER) study design and rationale
2016
|
|
| 2016
|
The Association Between Antihypertensive Medication Nonadherence and Visit-to-Visit Variability of Blood Pressure: Findings From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
2016
|
|
| 2016
|
Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years a randomized clinical trial
2016
|
|
| 2016
|
HOPE-3 and SPRINT: two landmark trials with different outcomes?
2016
|
|
| 2016
|
Prevalence of pseudoresistant hypertension due to inaccurate blood pressure measurement
2016
|
|
| 2016
|
Refractory hypertension: A novel phenotype of antihypertensive treatment failure
2016
|
|
| 2016
|
Urinary sodiumexcretion predicts blood pressure response to spironolactone in patients with resistant hypertension independent of aldosterone status
2016
|
|
| 2016
|
Treatment of Hypertension in Patients with Coronary Artery Disease. A Case-Based Summary of the 2015 AHA/ACC/ASH Scientific Statement
2016
|
|
| 2016
|
CardioPulse. The SPRINT trial results
2016
|
|
| 2016
|
The SPRINT trial results
2016
|
|
| 2016
|
Visit-to-visit variability of BP and CKD outcomes: Results from the ALLHAT
2016
|
|
| 2016
|
Patterns and Correlates of Baseline Thiazide-Type Diuretic Prescription in the Systolic Blood Pressure Intervention Trial
2016
|
|
| 2016
|
Targeted delivery of human iPS-ECs overexpressing IL-8 receptors inhibits neointimal and inflammatory responses to vascular injury in the rat
2016
|
|
| 2016
|
SPS3 Evidence Supports Intensive Blood Pressure Control
2016
|
|
| 2016
|
Ambulatory blood pressure monitoring in individuals with HIV: A systematic review and meta-analysis
2016
|
|
| 2016
|
SPRINT Trial Results: Latest News in Hypertension Management
2016
|
|
| 2016
|
The J-curve phenomenon revisited again: SPRINT outcomes favor target systolic blood pressure below 120 mmHg
2016
|
|
| 2016
|
Cardiovascular care for older adults: Hypertension and stroke in the older adult
2016
|
|
| 2016
|
Impact of renal denervation on patients with obstructive sleep apnea and resistant hypertension – Insights from the SYMPLICITY HTN-3 trial
2016
|
|
| 2016
|
Should Antihypertensive Treatment Recommendations Differ in Patients with and Without Coronary Heart Disease? (from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial [ALLHAT])
2016
|
|
| 2015
|
A randomized trial of intensive versus standard blood-pressure control
2015
|
|
| 2015
|
An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial
2015
|
|
| 2015
|
Visit-to-visit variability of blood pressure and coronary heart disease, stroke, heart failure, and mortality a cohort study
2015
|
|
| 2015
|
Estrogen and cardiovascular disease: Is timing everything?
2015
|
|
| 2015
|
Apparent treatment-resistant hypertension among individuals with history of stroke or transient ischemic attack
2015
|
|
| 2015
|
Tribute: John H. Laragh, MD
2015
|
|
| 2015
|
Treatment of Hypertension in Patients with Coronary Artery Disease: A Scientific Statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension
2015
|
|
| 2015
|
Less-tight versus tight control of hypertension in pregnancy
2015
|
|
| 2015
|
Less-tight versus tight control of hypertension in pregnancy
2015
|
|
| 2015
|
Treatment of hypertension in patients with coronary artery disease: A scientific statement from the american heart association, american college of cardiology, and american society of hypertension
2015
|
|
| 2015
|
Effect of spironolactone on diastolic function in hypertensive left ventricular hypertrophy
2015
|
|
| 2015
|
Regional Heterogeneity in 3D Myocardial Shortening in Hypertensive Left Ventricular Hypertrophy: A Cardiovascular CMR Tagging Substudy to the Life Study.
2015
|
|
| 2015
|
Predictors of blood pressure response in the SYMPLICITY HTN-3 trial
2015
|
|
| 2015
|
12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension the SYMPLICITY HTN-3 trial
2015
|
|
| 2015
|
Baseline characteristics of African Americans in the Systolic Blood Pressure Intervention Trial
2015
|
|
| 2015
|
Correlations of plasma renin activity and aldosterone concentration with ambulatory blood pressure responses to nebivolol and valsartan, alone and in combination, in hypertension
2015
|
|
| 2015
|
Is Blood Pressure Control for Stroke Prevention the Correct Goal?: The Lost Opportunity of Preventing Hypertension
2015
|
|
| 2015
|
New Approaches in the Treatment of Hypertension
2015
|
|
| 2015
|
Refractory hypertension: Evidence of heightened sympathetic activity as a cause of antihypertensive treatment failure
2015
|
|
| 2015
|
Treatment of hypertension in patients with coronary artery disease: A scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension
2015
|
|
| 2015
|
Treatment of hypertension in patients with coronary artery disease: A scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension
2015
|
|
| 2014
|
Triple-combination treatment with olmesartan medoxomil/amlodipine/ hydrochlorothiazide in hispanic/latino patients with hypertension: The trinity study
2014
|
|
| 2014
|
Update on Clinical Guidelines for Treatment of Hypertension
2014
|
|
| 2014
|
Antihypertensive medication classes used among medicare beneficiaries initiating treatment in 2007-2010
2014
|
|
| 2014
|
Low sodium intake - Cardiovascular health benefit or risk?
2014
|
|
| 2014
|
Determination of prevalence, risk factors, and comorbidities in a large, population-based cohort
2014
|
|
| 2014
|
Hypertension Management by Practice Guidelines
2014
|
|
| 2014
|
2014 Evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8)
2014
|
|
| 2014
|
2014 evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the eighth joint national committee (JNC 8)
2014
|
|
| 2014
|
A controlled trial of renal denervation for resistant hypertension
2014
|
|
| 2014
|
Age and the effectiveness of anti-hypertensive therapy on improvement in diastolic function
2014
|
|
| 2014
|
Apparent treatment-resistant hypertension and risk for stroke, coronary heart disease, and all-cause mortality
2014
|
|
| 2014
|
Chlorthalidone versus hydrochlorothiazide in hypertension treatment: Do we have the evidence to decide?
2014
|
|
| 2014
|
Effect of chlorthalidone, amlodipine, and lisinopril on visit-to-visit variability of blood pressure: Results from the antihypertensive and lipid-lowering treatment to prevent heart attack trial
2014
|
|
| 2014
|
Estrogen effects on vascular inflammation are age dependent: Role of estrogen receptors
2014
|
|
| 2014
|
Guidelines for managing high blood pressure - Reply
2014
|
|
| 2014
|
Impact of renal denervation on 24-hour ambulatory blood pressure: Results from SYMPLICITY HTN-3
2014
|
|
| 2014
|
Incident ESRD and treatment-resistant hypertension: The reasons for geographic and racial differences in stroke (REGARDS) study
2014
|
|
| 2014
|
Inhibiting C-reactive protein for the treatment of cardiovascular disease: Promising evidence from rodent models
2014
|
|
| 2014
|
Proceedings from Duke resistant hypertension think tank
2014
|
|
| 2014
|
Rates, amounts, and determinants of ambulatory blood pressure monitoring claim reimbursements among Medicare beneficiaries
2014
|
|
| 2014
|
Renal denervation in treatment-resistant hypertension-Oslo RDN, Symplicity HTN-3 and INSPiRED randomized trials
2014
|
|
| 2014
|
Response to should more significance be granted to medication response to antihypertensives in patients with resistant hypertension?
2014
|
|
| 2014
|
Reversibility of left ventricular mechanical dysfunction in patients with hypertensive heart disease
2014
|
|
| 2014
|
Stroke outcomes among participants randomized to chlorthalidone, amlodipine or lisinopril in ALLHAT
2014
|
|
| 2014
|
Targeted delivery of pulmonary arterial endothelial cells overexpressing interleukin-8 receptors attenuates monocrotaline-induced pulmonary vascular remodeling
2014
|
|
| 2014
|
The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: The systolic blood pressure intervention trial (SPRINT)
2014
|
|
| 2014
|
The use of ambulatory blood pressure monitoring among Medicare beneficiaries in 2007-2010
2014
|
|
| 2014
|
Trends in hypertension prevalence, awareness, treatment, and control among us adults 80 years and older, 1988-2010
2014
|
|
| 2014
|
Updated guidelines for management of high blood pressure in Japan
2014
|
|
| 2013
|
Author Response to Lipid-Lowering in African Americans in ALLHAT-Optimism Bias?
2013
|
|
| 2013
|
Hypertension in women
2013
|
|
| 2013
|
Novel strategies for treatment of resistant hypertension
2013
|
|
| 2013
|
Revisiting the pre-hypertension debate: Increasing evidence for treatment-or not
2013
|
|
| 2013
|
Risk of Hospitalized Gastrointestinal Bleeding in Persons Randomized to Diuretic, ACE-Inhibitor, or Calcium-Channel Blocker in ALLHAT
2013
|
|
| 2013
|
The Human Side of Failed Hypertension Treatment
2013
|
|
| 2013
|
Blood pressure lowering effect of renal sympathetic denervation or placebo? - Building expectations for Symplicity-HTN 3
2013
|
|
| 2013
|
Relationships between metrics of visit-to-visit variability of blood pressure
2013
|
|
| 2013
|
Prevalence of apparent treatment-resistant hypertension among individuals with CKD
2013
|
|
| 2013
|
2013 European society of hypertension/European society of cardiology hypertension guidelines
2013
|
|
| 2013
|
Long-term follow-up of moderately hypercholesterolemic hypertensive patients following randomization to pravastatin vs usual care: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT)
2013
|
|
| 2013
|
Olmesartan/amlodipine/hydrochlorothiazide in obese participants with hypertension: A TRINITY subanalysis
2013
|
|
| 2013
|
Ovarian hormones and vascular disease
2013
|
|
| 2013
|
Primary cardiovascular prevention by Mediterranean diet - The PREDIMED trial
2013
|
|
| 2013
|
Endothelial cells overexpressing IL-8 receptor reduce cardiac remodeling and dysfunction following myocardial infarction
2013
|
|
| 2013
|
Mortality and morbidity during and after antihypertensive and lipid-lowering treatment to prevent heart attack trial: Results by sex
2013
|
|
| 2013
|
Changes in cardiovascular risk associated with phentermine and topiramate extended-release in participants with comorbidities and a body mass index ≥27 kg/m2
2013
|
|
| 2013
|
Reply to Visit-to-Visit Blood Pressure Variation: Time to Reanalyze All The Data From the TROPHY Study
2013
|
|
| 2013
|
Effect of antihypertensive therapy on ventricular-arterial mechanics, coupling, and efficiency
2013
|
|
| 2013
|
Association Between Antihypertensive Medication Adherence and Visit-to-Visit Variability of Blood Pressure
2013
|
|
| 2013
|
Randomized Study of Antihypertensive Efficacy and Safety of Combination Aliskiren/Valsartan vs Valsartan Monotherapy in Hypertensive Participants With Type 2 Diabetes Mellitus
2013
|
|
| 2013
|
The contributions of unhealthy lifestyle factors to apparent resistant hypertension: Findings from the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study
2013
|
|
| 2013
|
Increased dietary sodium is related to severity of obstructive sleep apnea in patients with resistant hypertension and hyperaldosteronism
2013
|
|
| 2012
|
Angiotensin receptor - Neprilysin inhibiton (ARNI) A novel therapeutic concept for management of hypertension and heart failure
2012
|
|
| 2012
|
J Curve in Hypertension
2012
|
|
| 2012
|
Blood Pressure Measurement Device, Number and Timing of Visits, and Intra-Individual Visit-to-Visit Variability of Blood Pressure
2012
|
|
| 2012
|
Direct renin inhibitors in hypertension Approaching the moment of truth
2012
|
|
| 2012
|
Vasorelaxing effects of estetrol in rat arteries
2012
|
|
| 2012
|
Acute O-GlcNAcylation prevents inflammation-induced vascular dysfunction
2012
|
|
| 2012
|
Catheter-based renal denervation for resistant hypertension: Rationale and design of the SYMPLICITY HTN-3 trial
2012
|
|
| 2012
|
Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease
2012
|
|
| 2012
|
Triple-Combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in black and non-black study participants with hypertension: the TRINITY randomized, double-blind, 12-week, parallel-group study.
2012
|
|
| 2012
|
Triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in black and non-black study participants with hypertension: The trinity randomized, double-blind, 12-week, parallel-group study
2012
|
|
| 2012
|
Estrogen modulates NFκB signaling by enhancing IκBα levels and blocking p65 binding at the promoters of inflammatory genes via estrogen receptor-β
2012
|
|
| 2012
|
Long-Term renal and cardiovascular outcomes in antihypertensive and Lipid-Lowering treatment to prevent heart attack trial (ALLHAT) participants by baseline estimated GFR
2012
|
|
| 2012
|
Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial
2012
|
|
| 2012
|
Management of hypertension in the elderly
2012
|
|
| 2012
|
Transforming growth factor-β regulates endothelin-1 signaling in the newborn mouse lung during hypoxia exposure
2012
|
|
| 2012
|
Endothelial cells overexpressing interleukin-8 receptors reduce inflammatory and neointimal responses to arterial injury
2012
|
|
| 2012
|
Efficacy and safety of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in study participants with hypertension and diabetes: A subpopulation analysis of the TRINITY study
2012
|
|
| 2012
|
Long-Term Efficacy and Safety of Triple-Combination Therapy With Olmesartan Medoxomil and Amlodipine Besylate and Hydrochlorothiazide for Hypertension
2012
|
|
| 2012
|
Long-term effects of incident diabetes mellitus on cardiovascular outcomes in people treated for hypertension the ALLHAT diabetes extension study
2012
|
|
| 2012
|
Antiplatelet therapy for transient ischemic attack
2012
|
|
| 2012
|
Increased time varying heart rate and cardiovascular risk in hypertension Benefit of selective I (f) channel inhibitor?
2012
|
|
| 2012
|
Both morning and evening dosing of nebivolol reduces trough mean blood pressure surge in hypertensive patients
2012
|
|
| 2012
|
Kidney disease: Improving global outcomes (KDIGO) blood pressure work group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease
2012
|
|
| 2012
|
Mortality and morbidity during and after the antihypertensive and lipid-lowering treatment to prevent heart attack trial
2012
|
|
| 2012
|
Prevalence and Correlates of Low Medication Adherence in Apparent Treatment-Resistant Hypertension
2012
|
|
| 2012
|
Refractory hypertension: Definition, prevalence, and patient characteristics
2012
|
|
| 2012
|
Renal sympathetic denervation for treatment of hypertension
2012
|
|
| 2012
|
Within-Visit Variability of Blood Pressure and All-Cause and Cardiovascular Mortality Among US Adults
2012
|
|
| 2011
|
24-Hour Efficacy and Safety of Triple-Combination Therapy With Olmesartan, Amlodipine, and Hydrochlorothiazide: The TRINITY Ambulatory Blood Pressure Substudy
2011
|
|
| 2011
|
An appropriate SCORE to assess cardiovascular risk in hypertension?
2011
|
|
| 2011
|
Can catheter-based renal denervation be used safely and effectively to substantially reduce blood pressure in treatment-resistant hypertensive patients?
2011
|
|
| 2011
|
Hypoxia induces downregulation of PPAR-γ in isolated pulmonary arterial smooth muscle cells and in rat lung via transforming growth factor-β signaling
2011
|
|
| 2011
|
Introduction
2011
|
|
| 2011
|
Reproducibility of visit-to-visit variability of blood pressure measured as part of routine clinical care
2011
|
|
| 2011
|
Long-term follow-up of participants with heart failure in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
2011
|
|
| 2011
|
Renal nerve ablation: Emerging role in therapeutics
2011
|
|
| 2011
|
cGMP inhibits TGF-β signaling by sequestering Smad3 with cytosolic β2-tubulin in pulmonary artery smooth muscle cells
2011
|
|
| 2011
|
O-GlcNAc modification of nfκb p65 inhibits tnf-α-induced inflammatory mediator expression in rat aortic smooth muscle cells
2011
|
|
| 2011
|
The relationship between renal impairment and left ventricular structure, function, and ventricular-arterial interaction in hypertension
2011
|
|
| 2011
|
Transforming growth factor-β inhibits myocardial PPARγ expression in pressure overload-induced cardiac fibrosis and remodeling in mice
2011
|
|
| 2011
|
High mortality explained by mildly elevated blood pressure in Scandinavian adolescent conscripts A plea for early drug treatment?
2011
|
|
| 2011
|
Hypoxia-induced inhibition of lung development is attenuated by the peroxisome proliferator-activated receptor-γ agonist rosiglitazone
2011
|
|
| 2011
|
Response to intervisit blood pressure variability and outcome: Is heart rate a missing confounder?
2011
|
|
| 2011
|
ACCF/AHA 2011 expert consensus document on hypertension in the elderly: A report of the american college of cardiology foundation task force on clinical expert consensus documents
2011
|
|
| 2011
|
ACCF/AHA 2011 expert consensus document on hypertension in the elderly: A report of the American college of cardiology foundation task force on clinical expert consensus documents
2011
|
|
| 2011
|
Rationale for the use of multiple blockers of the renin-angiotensin- aldosterone system in specific patient populations
2011
|
|
| 2011
|
The role of ambulatory blood pressure monitoring compared with clinic and home blood pressure measures in evaluating moderate versus intensive treatment of hypertension with amlodipine/valsartan for patients uncontrolled on angiotensin receptor blocker monotherapy
2011
|
|
| 2011
|
Treatment of high blood pressure in acute stroke - The SCAST Study
2011
|
|
| 2011
|
Effectiveness-based guidelines for the prevention of cardiovascular disease in women - 2011 Update: A guideline from the American Heart Association
2011
|
|
| 2011
|
Effectiveness-based guidelines for the prevention of cardiovascular disease in women-2011 update: A Guideline from the American Heart Association
2011
|
|
| 2011
|
New challenges in blood pressure goals and assessment
2011
|
|
| 2011
|
The relationship between visit-to-visit variability in systolic blood pressure and all-cause mortality in the general population: Findings from NHANES III, 1988 to 1994
2011
|
|
| 2011
|
ACCF/AHA 2011 expert consensus document on hypertension in the elderly: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents Developed in Collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology,
2011
|
|
| 2011
|
Adherence and persistence with taking medication to control high blood pressure.
2011
|
|
| 2011
|
Antihypertensive therapy and cancer risks?
2011
|
|
| 2011
|
Moderate versus intensive treatment of hypertension using amlodipine/valsartan and with the addition of hydrochlorothiazide for patients uncontrolled on angiotensin receptor blocker monotherapy: Results in racial/ethnic subgroups
2011
|
|
| 2011
|
Moderate versus intensive treatment of hypertension with amlodipine/valsartan for patients uncontrolled on angiotensin receptor blocker monotherapy
2011
|
|
| 2010
|
Cardiovascular risks in HIV patients
2010
|
|
| 2010
|
Comparison of the antihypertensive efficacy of irbesartan/HCTZ and valsartan/HCTZ combination therapy: Impact of age and gender
2010
|
|
| 2010
|
Long-term efficacy of a combination of amlodipine and olmesartan medoxomilhydrochlorothiazide in patients with hypertension stratified by age, race and diabetes status: A substudy of the COACH trial
2010
|
|
| 2010
|
Have the renin-angiotensin-aldosterone system perturbations in cardiovascular disease been exhausted?
2010
|
|
| 2010
|
Efficacy of an olmesartan medoxomil-based treatment algorithm in patients stratified by age, race, or sex
2010
|
|
| 2010
|
Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension
2010
|
|
| 2010
|
Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: A preliminary report
2010
|
|
| 2010
|
Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study
2010
|
|
| 2010
|
A stitch saves time and lowers blood pressure
2010
|
|
| 2010
|
C-reactive protein-mediated vascular injury requires complement
2010
|
|
| 2010
|
Prevention of Microalbuminuria in Patients With Type 2 Diabetes: What Do We Know?
2010
|
|
| 2010
|
The transcription factor ETS-1 mediates proinflammatory responses and neointima formation in carotid artery endoluminal vascular injury
2010
|
|
| 2010
|
Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism: A prospective clinical study
2010
|
|
| 2010
|
Editorial: Blood pressure and migration
2010
|
|
| 2010
|
Editorial: Hypertension research into the new millennium
2010
|
|
| 2010
|
ASH position paper: dietary approaches to lower blood pressure.
2010
|
|
| 2010
|
Combination therapy in hypertension.
2010
|
|
| 2010
|
Treatment of hypertension in patients with diabetes--an update.
2010
|
|
| 2010
|
When and how to use self (home) and ambulatory blood pressure monitoring.
2010
|
|
| 2010
|
Effect of intensive versus standard blood pressure lowering on diastolic function in patients with uncontrolled hypertension and diastolic dysfunction
2010
|
|
| 2010
|
Inhibition of transforming growth factor-β signaling induces left ventricular dilation and dysfunction in the pressure-overloaded heart
2010
|
|
| 2010
|
Angiotensin receptor blockers and cancer - Relationship dismissed by VALUE data while waiting for EMA and FDA reports
2010
|
|
| 2010
|
Editorial: Blood Pressure celebrates 20 years of dedication to Nordic hypertension research
2010
|
|
| 2010
|
Editorial: Blood pressure variability: Emerging role in risk assessment and therapeutics
2010
|
|
| 2010
|
Impact of olmesartan on blood pressure, endothelial function, and cardiovascular outcomes
2010
|
|
| 2010
|
Prehypertension: Epidemiology, consequences and treatment
2010
|
|
| 2009
|
Does GISSI-AF change the concept of using RAS inhibitors in the primary prevention of atrial fibrillation in hypertensive patients?
2009
|
|
| 2009
|
The J-curve phenomenon revisited
2009
|
|
| 2009
|
Editorial: Critical aspects in hypertension diagnosis and treatment
2009
|
|
| 2009
|
Editorial: Should we treat prehypertension?
2009
|
|
| 2009
|
Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: The Losartan Intervention for Endpoint reduction in hypertension study
2009
|
|
| 2009
|
Reduction of blood pressure in patients with treatment-resistant hypertension
2009
|
|
| 2009
|
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
2009
|
|
| 2009
|
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
2009
|
|
| 2009
|
An evaluation of the efficacy of olmesartan medoxomil in Black patients with hypertension
2009
|
|
| 2009
|
Safety and tolerability of fixed-dose irbesartanhydrochlorothiazide for rapid control of severe hypertension
2009
|
|
| 2009
|
Subgroup analyses of an efficacy and safety study of concomitant administration of amlodipine besylate and olmesartan medoxomil: Evaluation by baseline hypertension stage and prior antihypertensive medication use
2009
|
|
| 2009
|
ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses: Reply
2009
|
|
| 2009
|
Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: Results from a randomized trial
2009
|
|
| 2009
|
Hypertension in the Elderly
2009
|
|
| 2009
|
ONTARGET, TRANSCEND and PROFESS - Clarifying, confusing or misleading?
2009
|
|
| 2009
|
ASH Position Paper: Dietary approaches to lower blood pressure.
2009
|
|
| 2009
|
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors.
2009
|
|
| 2009
|
ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses
2009
|
|
| 2009
|
Hormone therapy of premature ovarian failure the case for "natural" estrogen
2009
|
|
| 2009
|
Loss of Thy-1 inhibits alveolar development in the newborn mouse lung
2009
|
|
| 2009
|
Facts and fallacies of blood pressure control in recent trials: implications in the management of patients with hypertension
2009
|
|
| 2009
|
Angiotensin receptor blocker and dihydropyridine calcium channel blocker combinations: An emerging strategy in hypertension therapy
2009
|
|
| 2009
|
Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: The Losartan Intervention for Endpoint reduction in hypertension study
2009
|
|
| 2009
|
Estrogen and mechanisms of vascular protection
2009
|
|
| 2009
|
Sleep Apnea, Aldosterone, and Resistant Hypertension
2009
|
|
| 2009
|
A true champion of Hungarian kidney research and nephrology education--tribute to László Rosivall.
2009
|
|
| 2009
|
Critical aspects in hypertension diagnosis and treatment
2009
|
|
| 2009
|
Diastolic dysfunction and heart failure with preserved ejection fraction: rationale for RAAS antagonist/CCB combination therapy
2009
|
|
| 2009
|
EXCEED: Exforge®-intensive control of hypertension to evaluate efficacy in diastolic dysfunction: Study rationale, design, and participant characteristics
2009
|
|
| 2009
|
Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension
2009
|
|
| 2009
|
Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: The Losartan Intervention For End point reduction in hypertension (LIFE) study
2009
|
|
| 2009
|
Protein O-GlcNAcylation: A new signaling paradigm for the cardiovascular system
2009
|
|
| 2008
|
Benefits of hypertension management in diabetes: An opportunity not to be missed
2008
|
|
| 2008
|
Combining RAAS and calcium channel blockade: ACCOMPLISH in perspective
2008
|
|
| 2008
|
More focus on therapeutic targets and improved tolerability in hypertension
2008
|
|
| 2008
|
Aliskiren and valsartan in stage 2 hypertension: Subgroup analysis of a randomized, double-blind study
2008
|
|
| 2008
|
ASH position paper: Treatment of hypertension in patients with diabetes - An update
2008
|
|
| 2008
|
Hypertension in women
2008
|
|
| 2008
|
Management of older hypertensive patients
2008
|
|
| 2008
|
More focus on therapeutic targets and improved tolerability in hypertension.
2008
|
|
| 2008
|
Results of an olmesartan medoxomil-based treatment regimen in hypertensive patients
2008
|
|
| 2008
|
Renin Inhibitors: Novel Agents for Renoprotection or a Better Angiotensin Receptor Blocker for Blood Pressure Lowering?
2008
|
|
| 2008
|
Role of oxygen availability in CFTR expression and function
2008
|
|
| 2008
|
Renin inhibition: Should it supplant ACE inhibitors and ARBS in high risk patients?
2008
|
|
| 2008
|
More is less? Optimal combination therapy for adequate blood pressure lowering in hypertension
2008
|
|
| 2008
|
Marked regional left ventricular heterogeneity in hypertensive left ventricular hypertrophy patients: A losartan intervention for endpoint reduction in hypertension (LIFE) cardiovascular magnetic resonance and echocardiographic substudy
2008
|
|
| 2008
|
Fixed combinations in the management of hypertension: Patient perspectives and rationale for development and utility of the olmesartan - Amlodipine combination
2008
|
|
| 2008
|
A stunning day in hypertension research - Results of ONTARGET, ACCOMPLISH and HYVET
2008
|
|
| 2008
|
Urgent need to address quality control issues of out-of-office blood pressure measurement and patient risk assessment
2008
|
|
| 2008
|
Increased protein O-GlcNAc modification inhibits inflammatory and neointimal responses to acute endoluminal arterial injury
2008
|
|
| 2008
|
Thiazide-induced dysglycemia: Call for research from a working group from the national heart, lung, and blood institute
2008
|
|
| 2008
|
Transforming growth factor-β signaling mediates hypoxia-induced pulmonary arterial remodeling and inhibition of alveolar development in newborn mouse lung
2008
|
|
| 2008
|
Characterization of resistant hypertension: Association between resistant hypertension, aldosterone, and persistent intravascular volume expansion
2008
|
|
| 2008
|
Achieving better blood pressure control
2008
|
|
| 2008
|
Achieving better blood pressure control.
2008
|
|
| 2008
|
Beyond brachial pressure effect.
2008
|
|
| 2008
|
A double-blind, randomized study evaluating losartan potassium monotherapy or in combination with hydrochlorothiazide versus placebo in obese patients with hypertension
2008
|
|
| 2008
|
Effects of losartan in women with hypertension and left ventricular hypertrophy: Results from the Losartan Intervention For Endpoint reduction in hypertension study
2008
|
|
| 2008
|
Mechanisms and treatment of resistant hypertension
2008
|
|
| 2008
|
Atrial natriuretic peptide inhibits transforming growth factor β-induced Smad signaling and myofibroblast transformation in mouse cardiac fibroblasts
2008
|
|
| 2008
|
Relation of dietary salt and aldosterone to urinary protein excretion in subjects with resistant hypertension
2008
|
|
| 2008
|
ASH 2008: "Living the Vision"
2008
|
|
| 2008
|
Exaggerated neointima formation in human C-reactive protein transgenic mice is IgG Fc receptor type I (FcγRI)-dependent
2008
|
|
| 2008
|
Role of matrix metalloproteinase-2 in newborn mouse lungs under hypoxic conditions
2008
|
|
| 2008
|
Should we prefer different drugs to treat hypertension in older and younger adults? Practical implications of clinical trials: American perspective
2008
|
|
| 2007
|
Hypertension: What it is; What it isn't; How to think about it, to prevent it, and to manage it
2007
|
|
| 2007
|
Ambulatory blood pressure adds to explaining benefits of AT-1 receptor blockade in the treatment of left ventricular hypertrophy
2007
|
|
| 2007
|
Hypertension: what it is; what it isn't; how to think about it, to prevent it, and to manage it. Interview by George D. Lundberg.
2007
|
|
| 2007
|
Hypertension and cardiovascular disease: Is arterial stiffness the heart of the matter
2007
|
|
| 2007
|
Aldosterone excess and resistance to 24-h blood pressure control
2007
|
|
| 2007
|
Dual inhibition of the renin system by aliskiren and valsartan
2007
|
|
| 2007
|
New ESH/ESC Guidelines signal progress in hypertension management
2007
|
|
| 2007
|
A Good Year
2007
|
|
| 2007
|
Where are we going? Beyond JNC 7.
2007
|
|
| 2007
|
Fixed combination of losartan and hydrochlorothiazide and reduction of risk of stroke
2007
|
|
| 2007
|
Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial
2007
|
|
| 2007
|
Blood pressure control - Slowly getting there through new strategies?
2007
|
|
| 2007
|
The role of endothelin-1 in human hypertension
2007
|
|
| 2007
|
Are current guidelines optimal for treatment of blood pressure in patients with coronary artery disease?
2007
|
|
| 2007
|
Estrogen modulates TNF-α-induced inflammatory responses in rat aortic smooth muscle cells through estrogen receptor-β activation
2007
|
|
| 2007
|
Mechanisms and treatment of resistant hypertension
2007
|
|
| 2007
|
Documentation of endpoint prevention with combination therapy in hypertension is urgently needed
2007
|
|
| 2007
|
A Major Paradigm Shift
2007
|
|
| 2007
|
Aliskiren and valsartan for antihypertensive therapy
2007
|
|
| 2007
|
The ALLHAT study revisited: do newer data from this trial and others indicate changes in treatment guidelines?
2007
|
|
| 2007
|
Treatment of hypertension in the prevention and management of ischemic heart disease: A scientific statement from the American Heart Association council for high blood pressure research and the councils on clinical cardiology and epidemiology and prevention
2007
|
|
| 2007
|
Does improving hypertension control involve more than just pills?: Commentary
2007
|
|
| 2007
|
Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women: 2007 Update
2007
|
|
| 2007
|
Aged rats lose vasoprotective and anti-inflammatory actions of estrogen in injured arteries
2007
|
|
| 2007
|
An Open Letter to ASH Members
2007
|
|
| 2007
|
Evidence-based guidelines for cardiovascular disease prevention in women: 2007 Update
2007
|
|
| 2007
|
Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy
2007
|
|
| 2007
|
ANP signaling inhibits TGF-β-induced Smad2 and Smad3 nuclear translocation and extracellular matrix expression in rat pulmonary arterial smooth muscle cells
2007
|
|
| 2007
|
Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension.
2007
|
|
| 2007
|
Endothelin-1 Mediates Hypoxia-Induced Increases in Vascular Collagen in the Newborn Mouse Lung
2007
|
|
| 2007
|
JASH Inaugural Issue
2007
|
|
| 2007
|
Renin inhibitors in the management of hypertension.
2007
|
|
| 2006
|
Beta-blockers as sub-optimal treatment for hypertension: Time for first-line therapy revision?
2006
|
|
| 2006
|
The question of whether diabetes and its cardiovascular risks can be prevented: A realistic DREAM?
2006
|
|
| 2006
|
Is there a new treatment for hypertensive disease in the horizon? Role of soluble guanylate cyclase
2006
|
|
| 2006
|
Proteasomal inhibition: A novel pathway for prevention of atherosclerosis and restenosis
2006
|
|
| 2006
|
Women and hypertension: What did we learn from the Women's Health Initiative?
2006
|
|
| 2006
|
Phosphatidylinositol-3-kinase signaling mediates vascular smooth muscle cell expression of periostin in vivo and in vitro
2006
|
|
| 2006
|
Eplerenone prevents adverse cardiac remodelling induced by pressure overload in atrial natriuretic peptide-null mice
2006
|
|
| 2006
|
Atrial natriuretic peptide-dependent modulation of hypoxia-induced pulmonary vascular remodeling
2006
|
|
| 2006
|
Salt Sensitivity, a Determinant of Blood Pressure, Cardiovascular Disease and Survival
2006
|
|
| 2006
|
Salt sensitivity, a determinant of blood pressure, cardiovascular disease and survival.
2006
|
|
| 2006
|
Feasibility of treating prehypertension with an angiotensin-receptor blocker
2006
|
|
| 2006
|
Pulsology rediscovered: Commentary on the Conduit Artery Function Evaluation (CAFE) study
2006
|
|
| 2006
|
Dominant negative mutation of the TGF-β eceptor blocks hypoxia-induced pulmonary vascular remodeling
2006
|
|
| 2006
|
American Society of Hypertension, Inc
Leadership Message
2006
|
|
| 2006
|
Efficacy and Safety of Irbesartan/HCTZ Combination Therapy As Initial Treatment for Rapid Control of Severe Hypertension
2006
|
|
| 2006
|
Incidence and predictors of angioedema in elderly hypertensive patients at high risk for cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
2006
|
|
| 2006
|
Metabolite ligands of estrogen receptor-β reduce primate coronary hyperreactivity
2006
|
|
| 2006
|
Treatment of isolated systolic hypertension in diabetes mellitus type 2
2006
|
|
| 2005
|
Hypertension
2005
|
|
| 2005
|
Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers
2005
|
|
| 2005
|
Estrogen treatment abrogates neointima formation in human C-reactive protein transgenic mice
2005
|
|
| 2005
|
The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study
2005
|
|
| 2005
|
Endothelin-A receptor blockade prevents and partially reverses neonatal hypoxic pulmonary vascular remodeling
2005
|
|
| 2005
|
Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: The LIFE (Losartan Intervention for Endpoint reduction in hypertension) study
2005
|
|
| 2005
|
Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy
2005
|
|
| 2005
|
Fixed-dose combinations in the management of hypertension: Defining the place of angiotensin receptor antagonists and hydrochlorothiazide
2005
|
|
| 2005
|
Conflicting and confusing data from the hypertension treatment trials: whom and what should you believe?
2005
|
|
| 2005
|
Ethnicity and blood pressure.
2005
|
|
| 2005
|
Gender and blood pressure.
2005
|
|
| 2005
|
New-onset diabetes in treated hypertensive patients--is it clinically significant? Roundtable discussion.
2005
|
|
| 2005
|
Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: Losartan intervention for endpoint reduction in hypertension study
2005
|
|
| 2005
|
Role of angiotensin receptor blockers as monotherapy in reaching blood pressure goals
2005
|
|
| 2005
|
Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: The Losartan Intervention for Endpoint reduction in hypertension study
2005
|
|
| 2005
|
The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study.
2005
|
|
| 2004
|
Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: The LIFE study
2004
|
|
| 2004
|
Atrial natriuretic peptide dose-dependently inhibits pressure overload-induced cardiac remodeling
2004
|
|
| 2004
|
Hypoxia-responsive growth factors upregulate periostin and osteopontin expression via distinct signaling pathways in rat pulmonary arterial smooth muscle cells
2004
|
|
| 2004
|
Estrogen modulates inflammatory mediator expression and neutrophil chemotaxis in injured arteries
2004
|
|
| 2004
|
Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy
2004
|
|
| 2004
|
Interview with Suzanne Oparil, MD. Interview by Marvin Moser, MD.
2004
|
|
| 2004
|
Hypertensive therapy: Part I
2004
|
|
| 2004
|
Alcohol consumption and cardiovascular risk in hypertensives with left ventricular hypertrophy: The LIFE study
2004
|
|
| 2004
|
Evidence-based guidelines for cardiovascular disease prevention in women
2004
|
|
| 2004
|
Evidence-based guidelines for cardiovascular disease prevention in women. American Heart Association scientific statement.
2004
|
|
| 2004
|
Summary of the American Heart Association's evidence-based guidelines for cardiovascular disease prevention in women.
2004
|
|
| 2004
|
Volume overload results in exaggerated cardiac hypertrophy in the atrial natriuretic peptide knockout mouse
2004
|
|
| 2004
|
Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women
2004
|
|
| 2004
|
Estradiol and Progestins Differentially Modulate Leukocyte Infiltration after Vascular Injury
2004
|
|
| 2004
|
Advanced glycation end-product cross-link breakers: A novel approach to cardiovascular pathologies related to the aging process
2004
|
|
| 2004
|
Essential hypertension in women
2004
|
|
| 2004
|
Hypertensive therapy: Part II.
2004
|
|
| 2004
|
Roundtable discussion: blood pressure goal attainment: meeting the challenge of the JNC 7's blood pressure goals and the role of renin-angiotensin-aldosterone system blockade.
2004
|
|
| 2004
|
The impact of serum uric acid on cardiovascular outcomes in the LIFE study
2004
|
|
| 2003
|
Albuminuria and Cardiovascular Risk in Hypertensive Patients with Left Ventricular Hypertrophy: The LIFE Study
2003
|
|
| 2003
|
Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
2003
|
|
| 2003
|
Pathogenesis of Hypertension
2003
|
|
| 2003
|
Hormone replacement therapy and inflammation: Interactions in cardiovascular disease
2003
|
|
| 2003
|
Response to renin-angiotensin system antagonists in hypertensive black subjects [2] (multiple letters)
2003
|
|
| 2003
|
Comparison of the SCOPE and LIFE results [2] (multiple letters)
2003
|
|
| 2003
|
Comparison of the SCOPE and LIFE results.
2003
|
|
| 2003
|
Effects of Losartan or Atenolol in Hypertensive Patients without Clinically Evident Vascular Disease: A Substudy of the LIFE Randomized Trial
2003
|
|
| 2003
|
Fibroblast growth factor mediates hypoxia-induced endothelin-A receptor expression in lung artery smooth muscle cells
2003
|
|
| 2003
|
Effects of pressure overload on extracellular matrix expression in the heart of the atrial natriuretic peptide-null mouse
2003
|
|
| 2003
|
The seventh report of the joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. The JNC 7 report
2003
|
|
| 2003
|
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report
2003
|
|
| 2003
|
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): Practical implications
2003
|
|
| 2003
|
Pressure-independent enhancement of cardiac hypertrophy in atrial natriuretic peptide-deficient mice
2003
|
|
| 2003
|
Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients
2003
|
|
| 2003
|
α2A-adrenergic receptors mediate sympathoinhibitory responses to atrial natriuretic peptide in the mouse anterior hypothalamic nucleus
2003
|
|
| 2003
|
Secondary prevention of coronary heart disease in women: A call to action
2003
|
|
| 2003
|
Improving outcomes for women after coronary artery bypass grafting: A case for prevention
2003
|
|
| 2003
|
Long-Term Safety and Efficacy of the Selective Aldosterone Blocker Eplerenone in Patients with Essential Hypertension
2003
|
|
| 2003
|
The neointimal response ot endovascular injury is increased in obese Zucker rats
2003
|
|
| 2002
|
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
2002
|
|
| 2002
|
Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT)
2002
|
|
| 2002
|
Endothelin-A receptor blockade in porcine pulmonary hypertension
2002
|
|
| 2002
|
Endothelin-A receptor blockade in porcine pulmonary hypertension.
2002
|
|
| 2002
|
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: A Losartan Intervention For Endpoint reduction (LIFE) substudy
2002
|
|
| 2002
|
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study
2002
|
|
| 2002
|
Fibroblast growth factor receptor-1 signaling induces osteopontin expression and vascular smooth muscle cell-dependent adventitial fibroblast migration in vitro
2002
|
|
| 2002
|
Drugs targeting the renin-angiotensin-aldosterone system
2002
|
|
| 2002
|
Differential ANG II generation in plasma and tissue of mice with decreased expression of the ACE gene
2002
|
|
| 2002
|
Dietary salt supplementation selectively downregulates NPR-C receptor expression in kidney independently of ANP
2002
|
|
| 2002
|
Differential ANG II generation in plasma and tissue of mice with decreased expression of the ACE gene.
2002
|
|
| 2002
|
The effect of antihypertensive drugs on the fetus
2002
|
|
| 2002
|
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol
2002
|
|
| 2002
|
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol
2002
|
|
| 2002
|
Hormone replacement therapy and hypertension
2002
|
|
| 2002
|
Blood pressure and NaCl-sensitive hypertension are influenced by angiotensin-converting enzyme gene expression in transgenic mice
2002
|
|
| 2002
|
Sex hormones and hypertension
2002
|
|
| 2002
|
Blood pressure and NaCl-sensitive hypertension are influenced by angiotensin-converting enzyme gene expression in transgenic mice.
2002
|
|
| 2002
|
Dietary salt supplementation selectively downregulates NPR-C receptor expression in kidney independently of ANP.
2002
|
|
| 2002
|
Are there meaningful differences between antihypertensive agents?
2002
|
|
| 2002
|
Are there meaningful differences in blood pressure control with current antihypertensive agents?
2002
|
|
| 2002
|
Comparative antihypertensive efficacy of olmesartan: comparison with other angiotensin II receptor antagonists
2002
|
|
| 2002
|
Do angiotensin receptor antagonists have benefits beyond blood pressure lowering?
2002
|
|
| 2002
|
Interview: Suzanne Oparil, MD
2002
|
|
| 2002
|
The effect of antihypertensive drugs on the fetus
2002
|
|
| 2001
|
Erratum: Comparative efficacy of olmesartan, losartan, valsartan and irbesartan in the control of essential hypertension (Journal of Clinical Hypertension (2001) vol. 3(5) (283-291, 318))
2001
|
|
| 2001
|
Estrogen depletion induces NaCl-sensitive hypertension in female spontaneously hypertensive rats
2001
|
|
| 2001
|
Estrogen depletion induces NaCl-sensitive hypertension in female spontaneously hypertensive rats.
2001
|
|
| 2001
|
Estrogen-induced vasoprotection is independent of inducible nitric oxide synthase expression: Evidence from the mouse carotid artery ligation model
2001
|
|
| 2001
|
Tyrosine kinase receptor activation inhibits NPR-C in lung arterial smooth muscle cells
2001
|
|
| 2001
|
Efficacy of perindopril in the treatment of systemic hypertension.
2001
|
|
| 2001
|
Efficacy of perindopril in the treatment of systemic hypertension
2001
|
|
| 2001
|
The American journal of cardiology: Introduction
2001
|
|
| 2001
|
Once-daily treatment of patients with hypertension: A placebo-controlled study of amlodipine and benazepril vs amlodipine or benazepril alone
2001
|
|
| 2001
|
Tyrosine kinase receptor activation inhibits NPR-C in lung arterial smooth muscle cells.
2001
|
|
| 2001
|
Cardiovascular effects of estrogen.
2001
|
|
| 2001
|
Efficacy and safety of losartan/hydrochlorothiazide in patients with severe hypertension
2001
|
|
| 2001
|
Genetic variation in angiotensin-converting enzyme does not prevent development of cardiac hypertrophy or upregulation of angiotensin II in response to aortocaval fistula
2001
|
|
| 2001
|
Hormone replacement therapy and stroke: Are the results surprising?
2001
|
|
| 2001
|
Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension
2001
|
|
| 2001
|
Effects of ACE inhibitors, calcium antagonists, and other blood pressure-lowering drugs
2001
|
|
| 2001
|
Health outcomes associated with calcium antagonists
2001
|
|
| 2001
|
Hypertension. Introduction.
2001
|
|
| 2001
|
Primary aldosteronism: A practical approach to diagnosis and treatment
2001
|
|
| 2001
|
Treating hypertension in the elderly - Whom to treat, when, and with what?
2001
|
|
| 2001
|
What do international guidelines say about therapy?
2001
|
|
| 2000
|
Endothelin and pulmonary hypertension
2000
|
|
| 2000
|
Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (Benazepril) with calcium antagonist (Either Nifedipine or Amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension
2000
|
|
| 2000
|
Factors affecting blood pressure responses to diet: The vanguard study
2000
|
|
| 2000
|
Calcium antagonists in cardiovascular disease: Clinical evidence from morbidity and mortality trials
2000
|
|
| 2000
|
Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: The life study
2000
|
|
| 2000
|
Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint.
2000
|
|
| 2000
|
The organum vasculosum of the lamina terminalis regulates noradrenaline release in the anterior hypothalamic nucleus
2000
|
|
| 2000
|
A randomized trial of improved weight loss with a prepared meal plan in overweight and obese patients impact on cardiovascular risk reduction
2000
|
|
| 2000
|
Estrogen attenuates integrin-β3-dependent adventitial fibroblast migration after inhibition of osteopontin production in vascular smooth muscle cells
2000
|
|
| 2000
|
Fenoldopam, a dopamine agonist, for hypertensive emergency: A multicenter randomized trial
2000
|
|
| 2000
|
Fenoldopam, a dopamine agonist, for hypertensive emergency: a multicenter randomized trial. Fenoldopam Study Group.
2000
|
|
| 2000
|
Estrogen-induced vasoprotection is estrogen receptor dependent: Evidence from the balloon-injured rat carotid artery model
2000
|
|
| 2000
|
Effects of short-term estrogen treatment on the neointimal response to balloon injury of rat carotid artery
2000
|
|
| 2000
|
Direct in vivo evidence demonstrating neointimal migration of adventitial fibroblasts after balloon injury of rat carotid arteries
2000
|
|
| 2000
|
Essential hypertension part II: Treatment
2000
|
|
| 2000
|
Essential hypertension. Part I: Definition and etiology
2000
|
|
| 2000
|
Antihypertensive drug therapy in the third millennium: Are there benefits beyond blood pressure?
2000
|
|
| 2000
|
Effects of increased consumption of fluid milk on energy and nutrient intake, body weight, and cardiovascular risk factors in healthy older adults
2000
|
|
| 2000
|
Endothelial dysfunction in the pulmonary vascular bed
2000
|
|
| 2000
|
Endothelin and pulmonary hypertension.
2000
|
|
| 2000
|
Hypertension in women
2000
|
|
| 2000
|
Newly emerging pharmacologic differences in angiotensin II receptor blockers
2000
|
|
| 2000
|
Newly emerging pharmacologic differences in angiotensin II receptor blockers.
2000
|
|
| 1999
|
Bradykinin in the heart: Friend or foe?
1999
|
|
| 1999
|
Estrogen attenuates the adventitial contribution to neointima formation in injured rat carotid arteries
1999
|
|
| 1999
|
Harriet Pearson Dustan.
1999
|
|
| 1999
|
Candesartan cilexetil in combination with low-dose hydrochlorothiazide is effective in severe hypertension.
1999
|
|
| 1999
|
Increased dietary micronutrients decrease serum homocysteine concentrations in patients at high risk of cardiovascular disease
1999
|
|
| 1999
|
Treating multiple-risk hypertensive populations.
1999
|
|
| 1999
|
Estrogen inhibits vascular smooth muscle cell-dependent adventitial fibroblast migration in vitro
1999
|
|
| 1999
|
Effects of candesartan cilexetil in patients with severe systemic hypertension
1999
|
|
| 1999
|
Effects of candesartan cilexetil in patients with severe systemic hypertension. Candesartan Cilexetil Study Investigators.
1999
|
|
| 1999
|
Proposed changes for NIH's Center for Scientific Review. Panel on Scientific Boundaries for Review. Center for Scientific Review Advisory Committee, National Institutes of Health.
1999
|
|
| 1999
|
Proposed changes for NIH's center for scientific review
1999
|
|
| 1999
|
Hypertension
1999
|
|
| 1999
|
Fenoldopam: A new parenteral antihypertensive: Consensus roundtable on the management of perioperative hypertension and hypertensive crises
1999
|
|
| 1999
|
Evidence for angiotensin-converting enzyme- and chymase-mediated angiotensin II formation in the interstitial fluid space of the dog heart in vivo
1999
|
|
| 1999
|
Guide to Preventive Cardiology for Women.AHA/ACC Scientific Statement Consensus panel statement.
1999
|
|
| 1999
|
Guide to preventive cardiology for women
1999
|
|
| 1999
|
AHA/ACC scientific statement: consensus panel statement. Guide to preventive cardiology for women. American Heart Association/American College of Cardiology.
1999
|
|
| 1999
|
A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension
1999
|
|
| 1999
|
A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension.
1999
|
|
| 1999
|
Journal of Cardiovascular Pharmacology: Introduction
1999
|
|
| 1999
|
Long-term morbidity and mortality trials with amlodipine
1999
|
|
| 1999
|
Management of the hypertensive patient with coronary artery disease.
1999
|
|
| 1999
|
Multicenter randomized trial of a comprehensive prepared meal program in type 2 diabetes
1999
|
|
| 1999
|
2-Tetradecylglycidic acid, an inhibitor of carnitine palmitoyltransferase-1, induces myocardial hypertrophy via the AT1 receptor
1999
|
|
| 1999
|
Arthur C. Corcoran Memorial Lecture. Hormones and vasoprotection.
1999
|
|
| 1999
|
Candesartan cilexetil in combination with low-dose hydrochlorothiazide is effective in severe hypertension.
1999
|
|
| 1999
|
Clinical experience with transdermal clonidine in African-American and Hispanic-American patients with hypertension: Evaluation from a 12-week prospective, open-label clinical trial in community-based clinics
1999
|
|
| 1999
|
Co-administration of an ACE-inhibitor (moexipril) and hormonal replacement therapy in postmenopausal women
1999
|
|
| 1999
|
Comparison of telmisartan with lisinopril in patients with mild-to- moderate hypertension
1999
|
|
| 1999
|
Dietary changes favorably affect bone remodeling in older adults
1999
|
|
| 1999
|
Dietary salt reduction in hypertension - What is the evidence and why is it still controversial?
1999
|
|
| 1999
|
Differential expression of angiotensin-converting enzyme and chymase in dogs with chronic mitral regurgitation
1999
|
|
| 1999
|
Differential expression of natriuretic peptides and their receptors in volume overload cardiac hypertrophy in the rat
1999
|
|
| 1999
|
Eprosartan versus enalapril in hypertensive patients with angiotensin- converting enzyme inhibitor-induced cough
1999
|
|
| 1999
|
Guide to preventive cardiology for women
1999
|
|
| 1999
|
Hypertension in women
1999
|
|
| 1999
|
Management of the hypertensive patient with coronary artery disease
1999
|
|
| 1999
|
Nontraditional cardiovascular risk factors
1999
|
|
| 1999
|
Nutritionally complete prepared meal plan to reduce cardiovascular risk factors: A randomized clinical trial
1999
|
|
| 1999
|
Recent outcome trials of newer antihypertensives
1999
|
|
| 1999
|
Treating multiple-risk hypertensive populations
1999
|
|
| 1998
|
Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension.
1998
|
|
| 1998
|
Healthier diets improve quality of life while reducing cardiovascular disease risk factors
1998
|
|
| 1998
|
Case study
1998
|
|
| 1998
|
The evolving role of angiotensin-II receptor blockers in cardiovascular risk reduction. Case study.
1998
|
|
| 1998
|
Effects of Candesartan cilexetil in patients with systemic hypertension
1998
|
|
| 1998
|
Effects of candesartan cilexetil in patients with systemic hypertension. Candesartan Cilexetil Study Investigators.
1998
|
|
| 1998
|
Garlic prevents hypoxic pulmonary hypertension in rats
1998
|
|
| 1998
|
Garlic prevents hypoxic pulmonary hypertension in rats.
1998
|
|
| 1998
|
Pathophysiology of sudden coronary death in women: Implications for prevention
1998
|
|
| 1998
|
An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan. Irbesartan/Losartan Study Investigators.
1998
|
|
| 1998
|
Antihypertensive treatment in postmenopausal women: Results from a prospective, randomized, double-blind, controlled study comparing an ACE inhibitor (Moexipril) with a diuretic (Hydrochlorothiazide)
1998
|
|
| 1998
|
Mibefradil, a T-channel-selective calcium antagonist: clinical trials in hypertension.
1998
|
|
| 1998
|
Managing the patient with hard-to-control hypertension
1998
|
|
| 1998
|
An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan
1998
|
|
| 1998
|
Characteristics of 9194 patients with left ventricular hypertrophy: The LIFE study
1998
|
|
| 1998
|
Comprehensive nutrition plan improves cardiovascular risk factors in essential hypertension
1998
|
|
| 1998
|
Comprehensive nutrition plan improves cardiovascular risk factors in essential hypertension.
1998
|
|
| 1998
|
Dose-responsive antihypertensive efficacy of valsartan, a new angiotensin II-receptor blocker
1998
|
|
| 1998
|
Mibefradil, a T-channel-selective calcium antagonist: Clinical trials in hypertension
1998
|
|
| 1998
|
The sexual dimorphism of high blood pressure
1998
|
|
| 1997
|
No role for NO in estrogen-mediated vasoprotection?
1997
|
|
| 1997
|
High blood pressure in women
1997
|
|
| 1997
|
Angiotensin II formation from ACE and chymase in human and animal hearts: Methods and species considerations
1997
|
|
| 1997
|
Hypoxia stimulates human preproendothelin-1 promoter activity in transgenic mice
1997
|
|
| 1997
|
Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations.
1997
|
|
| 1997
|
Hypoxia stimulates human preproendothelin-1 promoter activity in transgenic mice.
1997
|
|
| 1997
|
Volume-overload cardiac hypertrophy is unaffected by ACE inhibitor treatment in dogs
1997
|
|
| 1997
|
Volume-overload cardiac hypertrophy is unaffected by ACE inhibitor treatment in dogs
1997
|
|
| 1997
|
A 42-year-old man with hypertension
1997
|
|
| 1997
|
Estrogen restores endothelial cell function in an experimental model of vascular injury
1997
|
|
| 1997
|
Antihypertensive effects of mibefradil in the treatment of mild-to- moderate systemic hypertension
1997
|
|
| 1997
|
Antihypertensive effects of mibefradil in the treatment of mild-to-moderate systemic hypertension.
1997
|
|
| 1997
|
Dose-response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension
1997
|
|
| 1997
|
Volume-overload cardiac hypertrophy is unaffected by ACE inhibitor treatment in dogs.
1997
|
|
| 1997
|
Compartmentalization of angiotensin II generation in the dog heart: Evidence for independent mechanisms in intravascular and interstitial spaces
1997
|
|
| 1997
|
Blood pressures and cardiovascular homeostasis in mice having reduced or absent angiotensin-converting enzyme gene function.
1997
|
|
| 1997
|
Dose-response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension.
1997
|
|
| 1997
|
The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.
1997
|
|
| 1997
|
The orally active nonpeptide endothelin A-receptor antagonist A-127722 prevents and reverses hypoxia-induced pulmonary hypertension and pulmonary vascular remodeling in Sprague-Dawley rats
1997
|
|
| 1997
|
Scientists' statement regarding data on the sodium-hypertension relationship and sodium health claims on food labeling
1997
|
|
| 1997
|
Nutritional management of cardiovascular risk factors: A randomized clinical trial
1997
|
|
| 1997
|
ALLHAT and calcium channel blockers [3]
1997
|
|
| 1997
|
ALLHAT and calcium channel blockers. ALLHAT Research Group.
1997
|
|
| 1997
|
Blood pressure and metabolic responses to moderate sodium restriction in isradipine-treated hypertensive patients
1997
|
|
| 1997
|
Blood pressures and cardiovascular homeostasis in mice having reduced or absent angiotensin-converting enzyme gene function
1997
|
|
| 1997
|
Dietary compliance and cardiovascular risk reduction with a prepared meal plan compared with a self-selected diet
1997
|
|
| 1997
|
Erratum: Dose-response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension (American Journal of Hypertension (July 1997) 10 (735-742))
1997
|
|
| 1997
|
Fenoldopam: A novel, peripherally acting dopamine-1 agonist for parenteral treatment of hypertension
1997
|
|
| 1997
|
Gender and cardiovascular disease: Recent insights
1997
|
|
| 1997
|
Sexually dimorphic response of the balloon-injured rat carotid artery to hormone treatment
1997
|
|
| 1997
|
The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study rationale, design, and methods
1997
|
|
| 1997
|
The expanding role of calcium antagonists in cardiovascular disease
1997
|
|
| 1997
|
Tolerability profile of tasosartan, a long-acting angiotensin II AT1 receptor blocker, in the treatment of patients with essential hypertension
1997
|
|
| 1996
|
Hypoxia decreases atrial natriuretic peptide clearance receptor (ANP-CR) gene expression in peripheral organs, but not in the brain, of rats
1996
|
|
| 1996
|
Hypoxia stimulates human preproendothelin-1 (PPET-1) promoter activity in transgenic mice
1996
|
|
| 1996
|
Identification of the hypoxia-responsive element in the 5′ flanking region of human endothelin-1 gene
1996
|
|
| 1996
|
Selective enhancement of angiotensin converting enzyme (ACE) gene expression in the heart during the development and maintenance of pressure overload cardiac hypertrophy
1996
|
|
| 1996
|
Tbc11251, a highly selective endothelin-a receptor antagonist. prevents and reverses acute hypoxia-fnduced pulmonary hypertension in the rat
1996
|
|
| 1996
|
Atrial natriuretic peptide regulation of noradrenaline release in the anterior hypothalamic area of spontaneously hypertensive rats
1996
|
|
| 1996
|
White Coat Hypertension???Fact or Fancy?
1996
|
|
| 1996
|
Purification and assay methods for angiotensin-converting enzyme
1996
|
|
| 1996
|
Preventing heart attack and death in patients with coronary disease. Endorsed by the board of trustees of the American College of Cardiology.
1996
|
|
| 1996
|
Antihypertensive therapy in the era of evidence based medical practice: What to do until the facts are in
1996
|
|
| 1996
|
Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group.
1996
|
|
| 1996
|
Acute saline infusion decreases norepinephrine release in the anterior hypothalamic area.
1996
|
|
| 1996
|
Estrogen reduces myointimal proliferation after balloon injury of rat carotid artery
1996
|
|
| 1996
|
17-β estradiol but not medroxyprogesterone inhibits neointima formation after balloon injury of rat carotid arteries
1996
|
|
| 1996
|
17-β estradiol inhibits restenosis after coronary angioplasty in pigs
1996
|
|
| 1996
|
A-127722, an orally active antagonist of the endothelin-a receptor, retards the progression of chronic hypoxia induced pulmonary hypertension in the rat
1996
|
|
| 1996
|
Anterior hypothalamic norepinephrine, atrial natriuretic peptide, and hypertension
1996
|
|
| 1996
|
Antihypertensive therapy and atherosclerosis in coronary heart disease
1996
|
|
| 1996
|
Atrial natriuretic peptide blunts arterial baroreflex in spontaneously hypertensive rats
1996
|
|
| 1996
|
Cardiac renin angiotensin system in hypertrophy and the progression to heart failure
1996
|
|
| 1996
|
Cardiovascular risk reduction in women
1996
|
|
| 1996
|
Classic papers symposium of the southern clinical research meetings: White coat hypertension - Fact or fancy?
1996
|
|
| 1996
|
Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension
1996
|
|
| 1996
|
Estrogen, but not androgen, inhibits the proliferation of cultured vascular smooth muscle cells derived from male and female spontaneously hypertensive rats
1996
|
|
| 1996
|
Hypertension: Initial evaluation
1996
|
|
| 1996
|
Hypoxia decreases atrial natriuretic peptide clearance receptor gene expression in pulmonary vascular smooth muscle cells in situ
1996
|
|
| 1996
|
Hypoxia enhances promoter activity of human endothelin-1 gene in transgenic mice
1996
|
|
| 1996
|
Improved quality of life in patients with generalized cardiovascular metabolic disease on a prepared diet
1996
|
|
| 1996
|
Medroxyprogesterone attenuates estrogen-mediated inhibition of neointima formation after balloon injury of the rat carotid artery
1996
|
|
| 1996
|
Ovariectomy induces NaCl-sensitivity in female spontaneously hypertensive rats
1996
|
|
| 1996
|
Phenotypic characterization of transgenic mice with "knockout" for the angiotensin converting enzyme
1996
|
|
| 1996
|
Rationale and design for the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT)
1996
|
|
| 1996
|
Salt intake and plasma atrial natriuretic peptide and nitric oxide in hypertension
1996
|
|
| 1996
|
The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension
1996
|
|
| 1995
|
Increased ACE and chymase-like activity in cardiac tissue of dogs with chronic mitral regurgitation
1995
|
|
| 1995
|
Increased ACE and chymase-like activity in cardiac tissue of dogs with chronic mitral regurgitation.
1995
|
|
| 1995
|
ETA-receptor antagonist prevents and reverses chronic hypoxia-induced pulmonary hypertension in rat.
1995
|
|
| 1995
|
Sensitive method for quantitation of angiotensin-converting enzyme (ACE) activity in tissue
1995
|
|
| 1995
|
Hypertension in postmenopausal women: Pathophysiology and management
1995
|
|
| 1995
|
Calcium antagonists: Antihypertensive and vascular considerations
1995
|
|
| 1995
|
Hypertensive crisis since fdr – a partial victory
1995
|
|
| 1995
|
Acute hypertension increases norepinephrine release in the anterior hypothalamic area.
1995
|
|
| 1995
|
Cardiovascular health at the crossroads: outlook for the 21st century. Presented at the 67th Scientific Sessions of the American Heart Association November 4, 1994 Dallas, Texas.
1995
|
|
| 1995
|
Selective downregulation of ANP-clearance-receptor gene expression in lung of rats adapted to hypoxia.
1995
|
|
| 1995
|
ET(A)-receptor antagonist prevents and reverses chronic hypoxia-induced pulmonary hypertension in rat
1995
|
|
| 1995
|
Effect of amlodipine on left ventricular mass in the amlodipine cardiovascular community trial
1995
|
|
| 1995
|
Effects of dietary salt on angiotensin peptides in kidney
1995
|
|
| 1995
|
Endothelin-A receptor antagonist prevents acute hypoxia-induced pulmonary hypertension in the rat
1995
|
|
| 1995
|
Endothelin-A receptor antagonist prevents acute hypoxia-induced pulmonary hypertension in the rat.
1995
|
|
| 1995
|
Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats
1995
|
|
| 1995
|
Fighting the NIH funding crisis
1995
|
|
| 1995
|
Gender and dietary NaCl in spontaneously hypertensive and Wistar-Kyoto rats
1995
|
|
| 1995
|
Initial medication selection for treatment of high blood pressure
1995
|
|
| 1995
|
Preventing heart attack and death in patients with coronary disease
1995
|
|
| 1995
|
Racial differences in the pathogenesis of hypertension
1995
|
|
| 1995
|
SSCI founders medal recipient's address
1995
|
|
| 1995
|
Selective downregulation of ANP-clearance-receptor gene expression in lung of rats adapted to hypoxia
1995
|
|
| 1995
|
The Elusive Role of Atrial Natriuretic Peptide in Hypertension
1995
|
|
| 1994
|
Increased endothelin receptor gene expression in hypoxic rat lung.
1994
|
|
| 1994
|
Antihypertensive therapy in the context of total cardiovascular risk: the rational basis for therapeutic recommendations.
1994
|
|
| 1994
|
Diurnal blood pressure variation and dietary salt in spontaneously hypertensive rats
1994
|
|
| 1994
|
Enhanced endothelin-1 and endothelin receptor gene expression in chronic hypoxia
1994
|
|
| 1994
|
Increased endothelin receptor gene expression in hypoxic rat lung
1994
|
|
| 1994
|
Increased endothelin receptor gene expression in hypoxic rat lung
1994
|
|
| 1994
|
Mithramycin inhibits myointimal proliferation after balloon injury of the rat carotid artery in vivo
1994
|
|
| 1994
|
Muscle sympathetic nervous system activity in black and caucasian hypertensive subjects
1994
|
|
| 1994
|
Role of anterior hypothalamic angiotensin II in the pathogenesis of salt sensitive hypertension in the spontaneously hypertensive rat
1994
|
|
| 1994
|
Sodium-proton (Na+/H+) exchange inhibition increases blood pressure in spontaneously hypertensive rat
1994
|
|
| 1994
|
The role of atrial natriuretic peptide and endothelin in hypoxia induced pulmonary hypertension.
1994
|
|
| 1993
|
Report of the task force on children and youth. American Heart Association.
1993
|
|
| 1993
|
Simplified method for quantitation of angiotensin peptides in tissue
1993
|
|
| 1993
|
Antihypertensive Therapy – Efficacy and Quality of Life
1993
|
|
| 1993
|
Coarctation induces alterations in basement membranes in the cardiovascular system
1993
|
|
| 1993
|
Excitatory sympathetic reflex in NaCl-sensitive spontaneously hypertensive rats
1993
|
|
| 1993
|
Nitric oxide mediates immune dysfunction in the spontaneously hypertensive rat
1993
|
|
| 1993
|
Normotensive blacks have heightened sympathetic response to cold pressor test
1993
|
|
| 1993
|
Presentation of the Southern Society for Clinical Investigation Founder's Medal to Dr. James A. Pittman, Jr.
1993
|
|
| 1993
|
Report of the task force on children and youth
1993
|
|
| 1992
|
Normobaric hypoxia stimulates endothelin-1 gene expression in the rat
1992
|
|
| 1992
|
Normobaric hypoxia stimulates endothelin-1 gene expression in the rat.
1992
|
|
| 1992
|
Converting-enzyme inhibitors increase converting-enzyme mRNA and activity in endothelial cells.
1992
|
|
| 1992
|
Preparative isolation of angiotensin-converting enzyme from human lung
1992
|
|
| 1992
|
Isolation of two distinct type I angiotensin II receptor genes
1992
|
|
| 1992
|
Effects of acute and chronic blockade of neutral endopeptidase with Sch 34826 on NaCl-sensitive hypertension in spontaneously hypertensive rats.
1992
|
|
| 1992
|
Androgen-dependent angiotensinogen and renin messenger RNA expression in hypertensive rats
1992
|
|
| 1992
|
Atrial natriuretic peptide modulates baroreceptor reflex in spontaneously hypertensive rat
1992
|
|
| 1992
|
Blocking hypothalamic AT1 receptors lowers blood pressure in salt- sensitive rats
1992
|
|
| 1992
|
Cicletanine blunts the pulmonary pressor response to acute hypoxia in rats
1992
|
|
| 1992
|
Converting-enzyme inhibitors increase converting-enzyme mRNA and activity in endothelial cells
1992
|
|
| 1992
|
Depressor effect of blocking angiotensin subtype 1 receptors in anterior hypothalamus
1992
|
|
| 1992
|
Effects of acute and chronic blockade of neutral endopeptidase with sch 34826 on nacl-sensitive hypertension in spontaneously hypertensive rats
1992
|
|
| 1992
|
Ganglion atrial natriuretic peptide in nacl sensitive spontaneously hypertensive rats
1992
|
|
| 1992
|
Neuronal control of the kidney: Contribution to hypertension
1992
|
|
| 1992
|
Preparative isolation of angiotensin-converting enzyme from human lung
1992
|
|
| 1992
|
Pressor effect of blocking atrial natriuretic peptide in nucleus tractus solitarii
1992
|
|
| 1992
|
Quantitation of hypothalamic atrial natriuretic peptide messenger RNA in hypertensive rats
1992
|
|
| 1992
|
Salt supplementation does not alter the pressor effect of blocking atrial natriuretic peptide in nucleus tractus solitarii
1992
|
|
| 1992
|
Sex difference in blood pressure of spontaneously hypertensive rats influenced by perinatal NaCl exposure
1992
|
|
| 1992
|
Spontaneously hypertensive rat: Lymphoid depression is age dependent and mediated via a mononuclear cell subpopulation
1992
|
|
| 1992
|
Spontaneously hypertensive rat: lymphoid depression is age dependent and mediated via a mononuclear cell subpopulation.
1992
|
|
| 1991
|
Decreased norepinephrine release in anterior hypothalamus of NaCl-sensitive spontaneously hypertensive rats during high NaCl intake
1991
|
|
| 1991
|
Dietary Ca2+ prevents NaCl-sensitive hypertension in spontaneously hypertensive rats via sympatholytic and renal effects
1991
|
|
| 1991
|
Dietary Ca2+ prevents NaCl-sensitive hypertension in spontaneously hypertensive rats via sympatholytic and renal effects.
1991
|
|
| 1991
|
The calcium antagonists in the 1990s. An overview.
1991
|
|
| 1991
|
Altered stores of atrial natriuretic peptide in specific brain nuclei of NaCl-sensitive spontaneously hypertensive rats.
1991
|
|
| 1991
|
Treatment of hypertensive crisis
1991
|
|
| 1991
|
Altered stores of atrial natriuretic peptide in specific brain nuclei of nacl-sensitive spontaneously hypertensive rats
1991
|
|
| 1991
|
Antihypertensive effect of cicletanine is exaggerated in NaCl-sensitive hypertension
1991
|
|
| 1991
|
Atrial natriuretic peptide in acute hypoxia-induced pulmonary hypertension in rats
1991
|
|
| 1991
|
Atrial natriuretic peptide inhibits sympathetic outflow in NaCi-sensitive spontaneously hypertensive rats
1991
|
|
| 1991
|
High NaCl diet enhances arterial baroreceptor reflex in NaCl-sensitive spontaneously hypertensive rats
1991
|
|
| 1991
|
Intrahypothalamic clonidine infusion prevents NaCl-sensitive hypertension
1991
|
|
| 1991
|
Neuronal angiotensin-converting enzyme (ACE) gene expression is increased by converting enzyme inhibitors (CEI)
1991
|
|
| 1991
|
The calcium antagonists in the 1990s an overview
1991
|
|
| 1990
|
Treatment of hypertensive crisis
1990
|
|
| 1990
|
In Reply
1990
|
|
| 1990
|
Dietary Ca2+ prevents NaCl-sensitive hypertension in spontaneously hypertensive rats by a sympatholytic mechanism.
1990
|
|
| 1990
|
High-performance liquid chromatographic determination of amiloride and its analogues in rat plasma.
1990
|
|
| 1990
|
An Assessment of Diltiazem and Hydrochlorothiazide in Hypertension
1990
|
|
| 1990
|
An Assessment of Diltiazem and Hydrochlorothiazide in Hypertension: Application of Factorial Trial Design to a Multicenter Clinical Trial of Combination Therapy
1990
|
|
| 1990
|
Vascular effects of kinins in trout and bradykinin metabolism by perfused gill.
1990
|
|
| 1990
|
Atrial natriuretic factor prevents NaCl-sensitive hypertension in spontaneously hypertensive rats
1990
|
|
| 1990
|
Atrial natriuretic peptide attenuates the development of pulmonary hypertension in rats adapted to chronic hypoxia
1990
|
|
| 1990
|
Atrial natriuretic peptide clearance receptor agonist lowers pulmonary pressure in hypoxic rats
1990
|
|
| 1990
|
Blockade of endogenous anterior hypothalamic atrial natriuretic peptide with monoclonal antibody lowers blood pressure in spontaneously hypertensive rats
1990
|
|
| 1990
|
Changes in cerebrospinal fluid Na+ concentration do not underlie hypertensive responses to dietary NaCl in spontaneously hypertensive rats
1990
|
|
| 1990
|
Dietary ca2+ increases natriuretic and diuretic responses to volume loading in nacl-sensitive spontaneously hypertensive rats
1990
|
|
| 1990
|
Dietary ca2+prevents NaCl-sensitive hypertension in spontaneously hypertensive rats by a sympatholytic mechanism
1990
|
|
| 1990
|
High-performance liquid chromatographic determination of amiloride and its analogues in rat plasma
1990
|
|
| 1990
|
Interleukin-2 does not attenuate hypertension in spontaneously hypertensive rats
1990
|
|
| 1990
|
Lesions of the anterior hypothalamic area increase arterial pressure in NaCl-sensitive spontaneously hypertensive rats
1990
|
|
| 1990
|
NaCl does not affect hypothalamic noradrenergic input in deoxycorticosterone acetate/NaCl and dahl salt-sensitive rats
1990
|
|
| 1990
|
Noninvasive Assessment of Renal Artery Stenosis by Combined Conventional and Color Doppler Ultrasound
1990
|
|
| 1990
|
Vascular effects of kinins in trout and bradykinin metabolism by perfused gill
1990
|
|
| 1989
|
Central mechanisms of hypertension.
1989
|
|
| 1989
|
Dietary NaCl loading enhances antihypertensive effect of guanabenz in spontaneously hypertensive rats.
1989
|
|
| 1989
|
Hypoxia stimulates endothelial cell angiotensin-converting enzyme antigen synthesis.
1989
|
|
| 1989
|
A simple method for concentration of biogenic amines and their metabolites from biological samples for analysis by HPLC-EC
1989
|
|
| 1989
|
Atrial natriuretic factor in NaCl-sensitive and NaCl-resistant spontaneously hypertensive rats
1989
|
|
| 1989
|
Atrial natriuretic peptide lowers pulmonary arterial pressure in patients with high altitude disease
1989
|
|
| 1989
|
Central mechanisms of hypertension
1989
|
|
| 1989
|
Dietary Ca2+ supplementation prevents the exaggerated responsiveness of anterior hypothalamic α2-adrenoceptors in NaCl-loaded spontaneously hypertensive rats
1989
|
|
| 1989
|
Dietary ca2+ prevents naci-induced exacerbation of hypertension and increases hypothalamic norepinephrine turnover in spontaneously hypertensive rats
1989
|
|
| 1989
|
Hemodynamic effects of arginine vasopressin in rats adapted to chronic hypoxia
1989
|
|
| 1989
|
Hypertension
1989
|
|
| 1989
|
Hypoxia stimulates endothelial cell angiotensin-converting enzyme antigen synthesis
1989
|
|
| 1989
|
Impaired reflex response to volume expansion in NaCl-sensitive spontaneously hypertensive rats
1989
|
|
| 1989
|
Purification of angiotensin-converting enzyme by gel high-performance liquid chromatography
1989
|
|
| 1989
|
Renal nerve contribution to NaCl-exacerbated hypertension in spontaneously hypertensive rats
1989
|
|
| 1989
|
Vasopressin lowers pulmonary artery pressure in hypoxic rats by releasing atrial natriuretic peptide
1989
|
|
| 1988
|
Enhanced cold pressor response in spontaneously hypertensive rats on high-NaCl diet
1988
|
|
| 1988
|
Lung MK 351A uptake after hypoxia adaptation and subsequent hyperoxia exposure
1988
|
|
| 1988
|
Enhanced cold pressor response in spontaneously hypertensive rats on high-NaCl diet.
1988
|
|
| 1988
|
Treating the older hypertensive patient-an overview
1988
|
|
| 1988
|
Effect of steric exclusion on the separation of proteins by hydrophilic size-exclusion chromatography.
1988
|
|
| 1988
|
Exaggerated depressor response to 6-iodoamiloride in NaCl-sensitive spontaneously hypertensive rats.
1988
|
|
| 1988
|
High NaCl diet increases anterior hypothalamic α2-adrenoceptors in SHR
1988
|
|
| 1988
|
Impaired release of atrial natriuretic factor in NaCl-loaded spontaneously hypertensive rats.
1988
|
|
| 1988
|
Captopril and the response to stress in the spontaneously hypertensive rat.
1988
|
|
| 1988
|
Altered angiotensin-converting enzyme in lung and extrapulmonary tissues of hypoxia-adapted rats
1988
|
|
| 1988
|
Atrial natriuretic peptide lowers pulmonary arterial pressure in hypoxia-adapted rats
1988
|
|
| 1988
|
Captopril and the response to stress in the spontaneously hypertensive rat
1988
|
|
| 1988
|
Central serotonergic alterations in deoxycorticosterone acetate/NaCl (DOCA/NaCl)-induced hypertension
1988
|
|
| 1988
|
Chronic infusion of atrial natriuretic peptide prevents pulmonary hypertension in hypoxia-adapted rats.
1988
|
|
| 1988
|
Current and future role of catapresan in the treatment of hypertension
1988
|
|
| 1988
|
Effect of steric exclusion on the separation of proteins by hydrophilic size-exclusion chromatography
1988
|
|
| 1988
|
Genetic basis of NaCl-sensitive hypertension
1988
|
|
| 1988
|
High NaCl diet reduces hypothalamic norepinephrine turnover in hypertensive rats
1988
|
|
| 1988
|
Hypothalamic microinjection of alpha2-adrenoceptor agonists causes greater sympathoinhibition in spontaneously hypertensive rats on high NaCl diets
1988
|
|
| 1988
|
Hypoxia-induced oxygen tolerance: Maintenance of endothelial metabolic function
1988
|
|
| 1988
|
Impaired release of atrial natriuretic factor in NaCl-loaded spontaneously hypertensive rats
1988
|
|
| 1988
|
Lung MK 351A uptake after hypoxia adaptation and subsequent hyperoxia exposure.
1988
|
|
| 1988
|
Perioperative red blood cell transfusion
1988
|
|
| 1988
|
Purification of an angiotensin II binding protein by using antibodies to a peptide encoded by angiotensin II complementary RNA
1988
|
|
| 1988
|
Rapid communication: Exaggerated depressor response to 6-iodoamiloride in NaCl-sensitive spontaneously hypertensive rats
1988
|
|
| 1988
|
The neural basis of salt sensitivity in the rat: Altered hypothalamic function
1988
|
|
| 1988
|
The use of complementary peptides in the purification of an angiotensin II binding protein
1988
|
|
| 1987
|
Role of vasopressin in the cardiovascular effects of LY171555, a selective dopamine D2 receptor agonist: Studies in conscious Brattleboro and Long-Evans rats
1987
|
|
| 1987
|
Role of the dissolution mechanism in determining chromatographic separation of biogenic amines from their precursors and metabolites by HPLC-EC
1987
|
|
| 1987
|
Altered responsiveness of regional brain dopamine and DOPAC levels to systemic administration of quinpirole, a dopamine D2 agonist, in DOCA/NaCl-hypertensive rats
1987
|
|
| 1987
|
De novo intrarenal formation of angiotensin II during control and enhanced renin secretion.
1987
|
|
| 1987
|
Exacerbation of hypertension by high chloride, moderate sodium diet in the salt-sensitive spontaneously hypertensive rat.
1987
|
|
| 1987
|
Sympathetic function in spontaneously hypertensive rats after chronic administration of captopril.
1987
|
|
| 1987
|
Two renal alpha 2-adrenergic receptor sites revealed by p-aminoclonidine binding.
1987
|
|
| 1987
|
Enhanced response to the inhibitory action of LY171555, a dopamine D2-agonist, on in vivo striatal dopamine release in DOCA/NaCl-hypertensive rats
1987
|
|
| 1987
|
Antihypertensive effect of enalapril in essential hypertension: Role of prostacyclin
1987
|
|
| 1987
|
Blunted responsiveness of posterior hypothalamic norepinephrine to quinpirole in DOCA/NaCl hypertensive rats
1987
|
|
| 1987
|
Continuous intravenous infusion of LY171555, a potent selective D2 receptor agonist, lowers blood pressure in the conscious rat
1987
|
|
| 1987
|
De novo intrarenal formation of angiotensin II during control and enhanced renin secretion
1987
|
|
| 1987
|
Exacerbation of hypertension by high chloride, moderate sodium diet in the salt-sensitive spontaneously hypertensive rat
1987
|
|
| 1987
|
Failure of renal denervation to attenuate hypertension in Dahl NaCl-sensitive rats
1987
|
|
| 1987
|
Hyperoxia-induced converting enzyme insufficiency in conscious rat: Cardiovascular effects
1987
|
|
| 1987
|
Hypertension produced by a high sodium diet in the borderline hypertensive rat (BHR)
1987
|
|
| 1987
|
Hypertension produced by a high sodium diet in the borderline hypertensive rat (BHR).
1987
|
|
| 1987
|
Hypoxia-induced inhibition of converting enzyme activity: Role in vascular regulation
1987
|
|
| 1987
|
Proteoglycans and hypertension: III: Aorta proteoglycans in Dahl salt-sensitive hypertensive rats
1987
|
|
| 1987
|
Renal catecholamines and α2-adrenergic receptors in salt-related and genetic hypertension
1987
|
|
| 1987
|
Spontaneously hypertensive rats exhibit reduced hypothalamic noradrenergic input after NaCl loading
1987
|
|
| 1987
|
Sympathetic function in spontaneously hypertensive rats after chronic administration of captopril
1987
|
|
| 1987
|
The antihypertensive effect of lisinopril compared to atenolol in patients with mild to moderate hypertension
1987
|
|
| 1987
|
The renal afferent nerves in the pathogenesis of hypertension
1987
|
|
| 1987
|
Two renal α2-adrenergic receptor sites revealed by p-aminoclonidine binding
1987
|
|
| 1987
|
Yohimbine-induced alterations of monoamine metabolism in the spontaneously hypertensive rat of the okamoto strain (SHR). II. The Central Nervous System (CNS)
1987
|
|
| 1987
|
Yohimbine-induced alterations of monoamine metabolism in the spontaneously hypertensive rat. I. The peripheral nervous system
1987
|
|
| 1986
|
Mechanism of the depressor action of LY171555, a selective dopamine D2 receptor agonist, in the anesthetized rat
1986
|
|
| 1986
|
Transport and hydrolysis of glucagon in the proximal nephron
1986
|
|
| 1986
|
Transport and hydrolysis of glucagon in the proximal nephron.
1986
|
|
| 1986
|
Angiotensin extraction by trout tissues in vivo and metabolism by the perfused gill.
1986
|
|
| 1986
|
Angiotensin extraction by trout tissues in vivo and metabolism by the perfused gill
1986
|
|
| 1986
|
Effects of locally formed angiotensin II on renal hemodynamics
1986
|
|
| 1986
|
Genetic and salt-related alterations in monoamine neurotransmitters in dahl salt-sensitive and salt-resistant rats
1986
|
|
| 1986
|
Impaired pulmonary conversion of angiotensin I to angiotensin II in rats exposed to chronic hypoxia
1986
|
|
| 1986
|
Increased vasopressinergic activity following DOCA administration in the rat
1986
|
|
| 1986
|
Mechanism of the pressor action of LY171555, a specific dopamine D2 receptor agonist, in the conscious rat
1986
|
|
| 1986
|
Proteoglycans and Hypertension I.A Biochemical and Ultrastructural Study of Aorta Glycosaminoglycans in Spontaneously Hypertensive Rats
1986
|
|
| 1986
|
Sensory denervation of the kidney attenuates renovascular hypertension in the rat
1986
|
|
| 1986
|
Sensory denervation of the kidney attenuates renovascular hypertension in the rat.
1986
|
|
| 1986
|
The sympathetic nervous system in clinical and experimental hypertension
1986
|
|
| 1985
|
Enhanced depressor effect of bromocriptine in the DOCA/NaCl hypertensive rat
1985
|
|
| 1985
|
Hyperresponsiveness of monoaminergic mechanisms in DOCA/NaCl hypertensive rats
1985
|
|
| 1985
|
Hypertension in a 74-year-old man with hydronephrosis and coronary disease.
1985
|
|
| 1985
|
Enhanced depressor effect of bromocriptine in the DOCA/NaCl hypertensive rat.
1985
|
|
| 1985
|
Hyperresponsiveness of monoaminergic mechanisms in DOCA/NaCl hypertensive rats.
1985
|
|
| 1985
|
Pathogenesis of ventricular hypertrophy.
1985
|
|
| 1985
|
Enhanced Depressor Effect of Muscimol in the DOCA/NaCl Hypertensive Rat: Evidence for Altered GABAergic Activity in Brain
1985
|
|
| 1985
|
Hypertension in a 74-year-old man with hydronephrosis and coronary disease principal discussant
1985
|
|
| 1985
|
Metabolism of angiotensin I by the trout gill
1985
|
|
| 1985
|
Morphologie substrates of sudden death: Questions and answers
1985
|
|
| 1985
|
Pathogenesis of ventricular hypertrophy
1985
|
|
| 1985
|
Reverse-phase separation and electrochemical detection of neuropeptides
1985
|
|
| 1984
|
The role of the posterior hypothalamic area in the pathogenesis of hypertension in the spontaneously hypertensive rat
1984
|
|
| 1984
|
Effect of central administration of MK-422 (the diacid form of enalapril) on the development of hypertension in the spontaneously hypertensive rat
1984
|
|
| 1984
|
Effect of central administration of MK-422 (the diacid form of enalapril) on the development of hypertension in the spontaneously hypertensive rat.
1984
|
|
| 1984
|
Myocardial cell hypertrophy or hyperplasia
1984
|
|
| 1984
|
Renal handling of glucagon and insulin.
1984
|
|
| 1984
|
Myocardial cell hypertrophy or hyperplasia.
1984
|
|
| 1984
|
Hormonal and haemodynamic responses to upper abdominal surgery during isoflurane and balanced anaesthesia
1984
|
|
| 1984
|
Renovascular hypertension in middle-aged females.
1984
|
|
| 1984
|
Subcellular sites of insulin hydrolysis in renal proximal tubules
1984
|
|
| 1984
|
Elevated catecholamines during cardiac surgery: Consequences of reperfusion of the postarrested heart
1984
|
|
| 1984
|
A randomized comparison of crystalloid and blood-containing cardioplegic solutions in 60 patients
1984
|
|
| 1984
|
Basal release of striatal dopamine is higher in spontaneously hypertensive rats than in Wistar Kyoto controls
1984
|
|
| 1984
|
Blood pressure oscillations in postsurgical hypertension during automatic control
1984
|
|
| 1984
|
Comprehensive drug management of hypertension
1984
|
|
| 1984
|
Mechanism of the depressor effect of bromocriptine in the spontaneously hypertensive rat
1984
|
|
| 1984
|
Myocardial cell hypertrophy or hyperplasia
1984
|
|
| 1984
|
Renal handling of glucagon
1984
|
|
| 1984
|
Subcellular sites of insulin hydrolysis in renal proximal tubules
1984
|
|
| 1983
|
Effect of hypoxia on the conversion of angiotensin I to II in cultured porcine pulmonary endothelial cells
1983
|
|
| 1983
|
Altered vascular reactivity and baroreflex sensitivity induced by chronic central administration of captopril in the spontaneously hypertensive rat
1983
|
|
| 1983
|
Attenuation of the development of spontaneous hypertension in rats by chronic central administration of captopril
1983
|
|
| 1983
|
Central catecholamine depletion, vasopressin, and blood pressure in the DOCA/NaCl rat
1983
|
|
| 1983
|
Central catecholamine depletion, vasopressin, and blood pressure in the DOCA/NaCl rat
1983
|
|
| 1983
|
Enalapril in low-renin essential hypertension
1983
|
|
| 1983
|
Immunoreactive bradykinin and [des-Arg9]-bradykinin in low-renin essential hypertension-before and after treatment with enalapril (MK421)
1983
|
|
| 1983
|
Intrarenal angiotensin I conversion at normal and reduced renal blood flow in the dog
1983
|
|
| 1983
|
Kidney function and sodium handling in the pregnant spontaneously hypertensive rat
1983
|
|
| 1983
|
Mechanism of the depressor effect of bromocriptine in the spontaneously hypertensive rat (SHR)
1983
|
|
| 1983
|
Role of the renal nerves in the maintenance of DOCA-salt hypertension in the rat. Influence on the renal vasculature and sodium excretion
1983
|
|
| 1982
|
Differences between renal tubular processing of glucagon and insulin
1982
|
|
| 1982
|
Importance of the renal nerves in the pathogenesis of experimental hypertension.
1982
|
|
| 1982
|
The AFCR: is there life after 41?
1982
|
|
| 1982
|
Importance of the renal nerves in established two-kidney, one clip Goldblatt hypertension.
1982
|
|
| 1982
|
Effect of hypoxia on the conversion of angiotensin I to II in the isolated perfused rat lung
1982
|
|
| 1982
|
1982: A critical year for hypertension
1982
|
|
| 1982
|
Angiotensin-converting enzyme in serum and in bronchoalveolar lavage in sarcoidosis
1982
|
|
| 1982
|
Central effects of prostaglandin E2 on blood pressure and plasma renin activity in rats role of the sympathoadrenal system and vasopressin
1982
|
|
| 1982
|
Central sympathectomy with 6-hydroxydopamine prevents DOCA/NaCl hypertension by mechanisms independent of vasopressin
1982
|
|
| 1982
|
Decrease in hypothalamic norepinephrine content following renal denervation in the one-kidney, one clip goldblatt hypertensive rat
1982
|
|
| 1982
|
Decrease in peripheral sympathetic nervous system activity following renal denervation or unclipping in the one-kidney one-clip Goldblatt hypertensive rat
1982
|
|
| 1982
|
Decrease in sympathetic nervous system activity and attenuation in response to stress following renal denervation in the one-kidney one-clip Goldblatt hypertensive rat.
1982
|
|
| 1982
|
Decrease in sympathetic nervous system activity and attenuation in response to stress following renal denervation in the one-kidney one-clip goldblatt hypertensive rat
1982
|
|
| 1982
|
Differences between renal tubular processing of glucagon and insulin
1982
|
|
| 1982
|
Gallium 67 citrate scanning and serum angiotensin converting enzyme levels in sarcoidosis
1982
|
|
| 1982
|
Importance of the renal Nerves in the Pathogenesis of Experimental Hypertension
1982
|
|
| 1982
|
Importance of the renal nerves in established Two-Kidney, one clip goldblatt hypertension
1982
|
|
| 1982
|
Increased noradrenaline content of hypothalamic nuclei in association with worsening of hypertension after high sodium intake in the young spontaneously hypertensive rat
1982
|
|
| 1982
|
Increased noradrenergic activity in hypothalamic nuclei of spontaneously hypertensive rats on high sodium intake
1982
|
|
| 1982
|
Neuronal and adrenomedullary catecholamine release in response to cardiopulmonary bypass in man
1982
|
|
| 1982
|
Prevention of hypertension in the spontaneously hypertensive rat by chronic central administration of captopril
1982
|
|
| 1982
|
Review of therapeutic modalities acting directly via central pathways
1982
|
|
| 1982
|
Review of therapeutic modalities acting directly via central pathways.
1982
|
|
| 1982
|
Sodium-neural interactions in the development of spontaneous hypertension
1982
|
|
| 1982
|
Sodium-neural interactions in the development of spontaneous hypertension.
1982
|
|
| 1982
|
The role of calcium in the control of renin release
1982
|
|
| 1981
|
A progress report on hypertension
1981
|
|
| 1981
|
Angiotensin II metabolism by tissues from developing rats
1981
|
|
| 1981
|
Catecholamine changes during cardiopulmonary bypass: The stress response and role of the lungs in modulating it
1981
|
|
| 1981
|
Central effects of prostaglandin E2 on blood pressure and plasma renin activity: Role of the sympathoadrenal system and vasopressin
1981
|
|
| 1981
|
Decreased serum angiotensin converting enzyme in adult respiratory distress syndrome associated with sepsis: a preliminary report.
1981
|
|
| 1981
|
Effects of sodium intake and Goldblatt hypertension on renin release in rat kidney slices
1981
|
|
| 1981
|
Effects of sodium intake and Goldblatt hypertension on renin release in rat kidney slices
1981
|
|
| 1981
|
Hypertension and oral contraceptives
1981
|
|
| 1981
|
Lofexidine and clonidine in moderate essential hypertension
1981
|
|
| 1981
|
Prevention of DOCA/NaCl hypertension in the rat by central sympatholytic treatment is unrelated to vasopressin
1981
|
|
| 1981
|
Renal function during reflexly activated catecholamine flow through an adrenorenal rete
1981
|
|
| 1981
|
Renal function during reflexly activated catecholamine flow through an adrenorenal rete
1981
|
|
| 1981
|
Role of the Renal Nerves in the Pathogenesis of One-Kidney Renal Hypertension in the Rat
1981
|
|
| 1980
|
Diurnal patterns and regulation of cortisol secretion in pregnancy
1980
|
|
| 1980
|
Drug management of hypertension
1980
|
|
| 1980
|
Effect of acute hypoxia on the pulmonary conversion of angiotensin I to angiotensin II in dogs
1980
|
|
| 1980
|
Effect of molecular size and structure on renal tubular processing of peptides
1980
|
|
| 1980
|
Hemodynamic Response to Vascular Expansion Following Immunosympathectomy in Spontaneously Hypertensive Rats
1980
|
|
| 1980
|
Importance of Renal Sympathetic Tone in the Development of DOCA-Salt Hypertension in the Rat
1980
|
|
| 1980
|
Lofexidine in essential hypertension: Double blind comparison with clonidine
1980
|
|
| 1980
|
Multiclinic double-blind evaluation of timolol combined with hydrochlorothiazide in essential hypertension
1980
|
|
| 1980
|
NMR observation of altered sodium interaction with human erythrocyte membranes of essential hypertensives
1980
|
|
| 1980
|
Pathogenesis of paroxysmal hypertension developing during and after coronary bypass surgery: A study of hemodynamic and humoral factors
1980
|
|
| 1980
|
Role of the renal sympathetic nerves in the development and maintenance of hypertension in the spontaneously hypertensive rat
1980
|
|
| 1980
|
The first year of hypertension
1980
|
|
| 1979
|
Hypertrophy in the denervated heart: A comparison of central sympatholytic treatment with 6-hydroxydopamine and peripheral sympathectomy with nerve growth factor antiserum
1979
|
|
| 1979
|
A simple method for determining the free cortisol index in plasma: measurements in human pregnancy
1979
|
|
| 1979
|
Clinical significance of serum angiotensin-converting enzyme levels in sarcoidosis
1979
|
|
| 1979
|
Desoxycorticosterone in normal pregnancy. II. Cortisol-dependent fluctuations in free plasma desoxycorticosterone
1979
|
|
| 1979
|
Effect of acute hypoxia on in-vivo conversion of angiotensin I to II in dogs
1979
|
|
| 1979
|
Hypertension: A new journal
1979
|
|
| 1979
|
Mechanism for renal tubular handling of angiotensin
1979
|
|
| 1979
|
Mechanism for renal tubular handling of angiotensin
1979
|
|
| 1979
|
Mechanism of angiotensin i converting enzyme inhibition by SQ20,881 (<Glu-Trp-Pro-Arg-Pro-Gln-Ile-Pro-Pro) in vivo: Further evidence for extrapulmonary conversion
1979
|
|
| 1979
|
Mechanism of postarrhythmic renal vasoconstriction in the anesthetized dog
1979
|
|
| 1979
|
Nomenclature for experimental renovascular hypertension. Report of the Nomenclature Committee of the Council for High Blood Pressure Research of the American Heart Association.
1979
|
|
| 1979
|
Regional myocyte size in normotensive and spontaneously hypertensive rats
1979
|
|
| 1979
|
Renal tubular handling of glucagon and insulin
1979
|
|
| 1979
|
Renal tubular transport and catabolism of proteins and peptides
1979
|
|
| 1979
|
The effect of renal denervation on the development of DOCA-salt hypertension in the rat
1979
|
|
| 1978
|
Desoxycorticosterone in normal pregnancy. I. Sequential studies of the secretory patterns of desoxycorticosterone, aldosterone, and cortisol
1978
|
|
| 1978
|
Inhibition of renin release from rat kidney slices by the angiotensins.
1978
|
|
| 1978
|
Effects of constituent amino acids on tubular handling of microinfused angiotensin II.
1978
|
|
| 1978
|
Effect of peripheral sympathectomy on left ventricular ultrastructure in young spontaneously hypertensive rats.
1978
|
|
| 1978
|
Calcium dependence of angiotensin II induced inhibition of renin release in vitro
1978
|
|
| 1978
|
Effect of peripheral sympathectomy on left ventricular ultrastructure in young spontaneously hypertensive rats
1978
|
|
| 1978
|
Effects of constituent amino acids on tubular handling of microinfused angiotensin II
1978
|
|
| 1978
|
In vivo and in vitro conversion of des-1-Asp angiotensin I to angiotensin III
1978
|
|
| 1978
|
Inhibition of renin release from rat kidney slices by the angiotensin
1978
|
|
| 1978
|
Myocardial hypertrophy and ventricular performance in the absence of hypertension in spontaneously hypertensive rats
1978
|
|
| 1978
|
Plasma angiotensin converting enzyme activity in mother and fetus
1978
|
|
| 1978
|
Report of the AFCR public policy committee: current legislative priorities
1978
|
|
| 1978
|
Report of the AFCR public policy committee: current legislative priorities
1978
|
|
| 1978
|
The mechanism of post-arrhythmic renal vasoconstriction in the dog
1978
|
|
| 1977
|
Handling of angiotensin II and oxytocin by renal tubular segments perfused in vitro
1977
|
|
| 1977
|
Sodium and mineralocorticoids in normal and abnormal pregnancy.
1977
|
|
| 1977
|
Changing patterns of corticoid responses to ACTH during normal pregnancy
1977
|
|
| 1977
|
Development of left ventricular hypertrophy in young spontaneously hypertensive rats after peripheral sympathectomy
1977
|
|
| 1977
|
Drug treatment of hypertension
1977
|
|
| 1977
|
Handling of angiotensin II and oxytocin by renal tubular segments perfused in vitro
1977
|
|
| 1977
|
Relation of renal hemodynamics to metabolism of angiotensin II by the canine kidney
1977
|
|
| 1977
|
Treatment of hypertension by computer and physician-A prospective controlled study
1977
|
|
| 1976
|
Altered angiotensin I conversion in pulmonary disease
1976
|
|
| 1976
|
Catecholamines, blood pressure, renin and myocardial function in the spontaneously hypertensive rat.
1976
|
|
| 1976
|
Inhibition of proximal tubular hydrolysis and reabsorption of bradykinin by peptides
1976
|
|
| 1976
|
Micropuncture evidence of rapid hydrolysis of bradykinin by rat proximal tubule
1976
|
|
| 1976
|
Mineralocorticoids in normal pregnancy.
1976
|
|
| 1976
|
The renin-angiotensin system in mother and fetus at cesarean section: a preliminary communication.
1976
|
|
| 1976
|
Theoretical approaches to estimation of plasma renin activity: a review and some original observations
1976
|
|
| 1976
|
Oral-Contraceptive-Induced Hypertension After Adrenalectomy and Hypophysectomy
1976
|
|
| 1976
|
Managing heart disease in pregnancy.
1976
|
|
| 1976
|
Catecholamines, blood pressure, renin and myocardial function in the spontaneously hypertensive rat
1976
|
|
| 1976
|
Digitalis assay and its clinical application
1976
|
|
| 1976
|
Effects of renal hemodynamics on metabolism of angiotensin II (AII) by the dog kidney
1976
|
|
| 1976
|
Inhibition of proximal tubular hydrolysis and reabsorption of angiotensin II by amino acid
1976
|
|
| 1976
|
Inhibition of proximal tubular hydrolysis of bradykinin
1976
|
|
| 1976
|
Myocardial function and renin in the spontaneously hypertensive rat after central and peripheral sympathectomy
1976
|
|
| 1976
|
Oral-Contraceptive-Induced Hypertension After Adrenalectomy and Hypophysectomy
1976
|
|
| 1976
|
Regulation of cortisol (F) secretion in pregnancy
1976
|
|
| 1976
|
Structural requirements for the inhibition of renin release in vitro by the angiotensins
1976
|
|
| 1976
|
Treatment of essential hypertension with a combination of hydrochlorothiazide, propranolol and methyldopa
1976
|
|
| 1975
|
Effect of progesterone on renal sodium handling in man: relation to aldosterone excretion and plasma renin activity
1975
|
|
| 1975
|
Fate of labeled angiotensin II microinfused into individual nephrons in the rat
1975
|
|
| 1975
|
Oral contraceptive pill hypertension
1975
|
|
| 1975
|
Plasma renin activity in hypertension.
1975
|
|
| 1975
|
Central catecholamine depletion and the prevention of hypertension
1975
|
|
| 1975
|
Handling of small peptides by rat renal tubules
1975
|
|
| 1975
|
Physician acceptance of computer recommended antihypertensive therapy
1975
|
|
| 1975
|
Prevention of Hypertension in the SH Rat: Effects of Differential Central Catecholamine Depletion
1975
|
|
| 1974
|
Studies of plasma bradykininases using radiolabelled substrates
1974
|
|
| 1974
|
The Renin-Angiotensin System
1974
|
|
| 1974
|
The Renin-Angiotensin System
1974
|
|
| 1974
|
The renin-angiotensin system (first of two parts).
1974
|
|
| 1974
|
Effects of ph and enzyme inhibitors on apparent generation of angiotensin i in human plasma
1974
|
|
| 1974
|
New polypeptide inhibitors of angiotensin conversion
1974
|
|
| 1974
|
Structural requirements for substrates and inhibitors of angiotensin I converting enzyme in vivo and in vitro
1974
|
|
| 1973
|
Heart disease in pregnancy
1973
|
|
| 1973
|
Mechanism of renal handling of angiotensin II in the dog
1973
|
|
| 1973
|
Metabolism of angiotensin II (AII) by dog kidney
1973
|
|
| 1973
|
Polypeptide inhibitors of angiotensin converting enzyme
1973
|
|
| 1973
|
Substrate requirements for angiotensin I conversion in vivo and in vitro.
1973
|
|
| 1972
|
Left-Superior-Vena-Cava Steal Syndrome
1972
|
|
| 1971
|
Mechanism of pulmonary conversion of angiotensin I to angiotensin II in the dog.
1971
|
|
| 1971
|
Renin in differential diagnosis of hypertension
1971
|
|
| 1970
|
In-vivo and in-vitro conversion of angiotensin I to angiotensin II in dog blood.
1970
|
|
| 1970
|
Role of renin in acute postural homeostasis.
1970
|
|
| 1966
|
Sex difference in fluid exchange during food deprivation in the rabbit.
1966
|
|
